EXHIBIT 7





CONSOLIDATED FINANCIAL STATEMENTS and SUPPLEMENTARY INFORMATION

September 30, 2021 and 2020 With Independent Auditor's Report and Government Reports in Accordance with *Government Auditing Standards* and the Uniform Guidance

September 30, 2021 and 2020

Table of Contents

	<u>Page(s)</u>
Independent Auditor's Report	1 - 2
Consolidated Financial Statements: Consolidated Balance Sheets Consolidated Statements of Operations Consolidated Statements of Changes in Net Assets Consolidated Statements of Cash Flows Notes to Consolidated Financial Statements	3 4 5 6 7 - 25
Supplementary Information: Consolidating Balance Sheets Consolidating Statements of Operations	26 - 27 28
 Independent Auditor's Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Consolidated Financial Statements Performed in Accordance with <i>Government Auditing Standards</i> Independent Auditor's Report on Compliance for the Major Federal Program; Report on Internal Control over Compliance; and Report on Schedule of Expenditures of Federal Awards 	29 - 30
Required by the Uniform Guidance Schedule of Expenditures of Federal Awards Notes on Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Year Findings and Questioned Costs	31 -32 33 34 35 - 37 38



INDEPENDENT AUDITOR'S REPORT

Board of Trustees Valley Regional Healthcare, Inc.

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of Valley Regional Healthcare, Inc. and Subsidiary, which comprise the consolidated balance sheets as of September 30, 2021 and 2020, and the related consolidated statements of operations, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implement-ation and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express opinions on these consolidated financial statements based on our audits. We conducted our audits in accordance with U.S. generally accepted auditing standards and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Valley Regional Healthcare, Inc. and Subsidiary as of September 30, 2021 and 2020, and the results of their operations, changes in their net assets, and their cash flows for the years then ended, in accordance with U.S. generally accepted accounting principles.

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. Schedules 1 and 2 are presented for purposes of additional analysis rather than to present the financial position and results of operations of the individual entities, and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audits of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with U.S. generally accepted auditing standards. In our opinion, Schedules 1 and 2 are fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated January 19, 2022 on our consideration of Valley Regional Healthcare, Inc. and Subsidiary's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Valley Regional Healthcare, Inc. and Subsidiary's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Valley Regional Healthcare, Inc. and Subsidiary's internal control over financial control over financial reporting and compliance.

Berry Dunn McNeil & Parker, LLC

Manchester, New Hampshire January 19, 2022

Consolidated Balance Sheets

September 30, 2021 and 2020

ASSETS

	<u>2021</u>	<u>2020</u>
Current assets		
Cash and cash equivalents	\$ 22,105,517	\$ 26,969,949
Short-term investments	152,584	149,218
Patient accounts receivable, net	4,048,637	4,085,605
Supplies	1,025,989	926,898
Prepaid expenses	399,299	359,438
Other accounts receivable	<u>2,157,297</u>	1,948,631
Total current assets	29,889,323	34,439,739
Assets limited as to use		
Internally designated for capital acquisitions and		
community service	23,393,340	19,013,030
By loan agreement	5,782,142	5,747,905
Cash with donor restrictions	3,077	3,077
Total assets limited as to use	29,178,559	24,764,012
Property and equipment, net	11,880,625	12,426,102
Long-term investments	9,624,228	4,947,859
Beneficial interests in perpetual trusts	5,117,482	4,219,722

Total assets	\$ <u>85,690,217</u>	\$ <u>80,797,434</u>
--------------	----------------------	----------------------

LIABILITIES AND NET ASSETS

	<u>2021</u>	<u>2020</u>
Current liabilities Current portion of long-term debt Accounts payable and accrued expenses Accrued compensated absences Accrued salaries and related amounts Estimated third-party payor settlements Medicare accelerated payments Paycheck Protection Program (PPP) refundable advance Deferred revenue Other current liabilities	\$ 340,902 3,316,629 1,202,385 479,640 4,437,080 6,447,560 - 268,087 763,301	\$ 330,011 3,009,768 1,204,357 1,033,144 3,208,225 8,114,726 4,020,400 530,162 825,884
Total current liabilities	17,255,584	22,276,677
Long-term debt, excluding current portion	17,597,942	17,929,214
Estimated third-party payor settlements, excluding current portion Total liabilities	<u>14,948,490</u> <u>49,802,016</u>	<u>14,948,490</u> <u>55,154,381</u>
Net assets Without donor restrictions With donor restrictions Total net assets	28,433,796 7,454,405 35,888,201	19,415,653 <u>6,227,400</u> <u>25,643,053</u>
Total liabilities and net assets	\$ <u>85,690,217</u>	\$ <u>80,797,434</u>

Consolidated Statements of Operations

Years Ended September 30, 2021 and 2020

Devenues, saine, and other compart without dense restrictions	<u>2021</u>	<u>2020</u>
Revenues, gains, and other support without donor restrictions Net patient service revenue	\$ 42,361,536	\$ 38,721,433
Other revenues Medicaid disproportionate share hospital direct payment revenue	1,304,189	1,590,419
U.S. Department of Health and Human Services stimulus revenue	3,802,644 -	- 4,931,273
PPP refundable advance revenue Grant revenue	4,020,400 <u>707,895</u>	- <u>360,781</u>
Total revenues, gains, and other support without	101,095	
donor restrictions	<u>52,196,664</u>	45,603,906
Expenses		
Salaries	19,952,181	19,410,941
Employee benefits	5,454,269	4,525,112
Professional fees	5,402,478	4,324,013
Supplies and other	12,249,012	11,582,673
Insurance	818,589	427,254
Depreciation and amortization	1,791,265	1,871,395
Interest	598,861	609,400
Medicaid enhancement tax	2,019,557	2,052,579
Total expenses	48,286,212	44,803,367
Operating income	3,910,452	800,539
Nonoperating gains (losses)		
Investment income	1,001,460	520,371
Change in net unrealized gains on equity investments	4,398,819	767,392
Other nonoperating (losses) gains, net	(6,287)	(4,574)
Nonoperating gains, net	5,393,992	1,283,189
Excess of revenues, gains, other support, and		
nonoperating gains over expenses	9,304,444	2,083,728
Change in net unrealized (losses) gains on investments	(353,437)	20,007
Net assets released for restrictions used for the purchase of property and equipment	67,136	
Change in net assets without donor restrictions	\$ <u>9,018,143</u>	\$ <u>2,103,735</u>

The accompanying notes are an integral part of these consolidated financial statements.

Consolidated Statements of Changes in Net Assets

Years Ended September 30, 2021 and 2020

	Without Donor <u>Restrictions</u>	With Donor Restrictions	<u>Total</u>
Balances, October 1, 2019	\$ <u>17,311,918</u>	\$ <u>6,049,237</u>	\$ <u>23,361,155</u>
Excess of revenues, gains, other support, and nonoperating gains over expenses Change in net unrealized gains on investments Net realized and unrealized gains on investments Net gain on beneficial interests in perpetual trusts Restricted investment income	2,083,728 20,007 - - -	- 61,376 76,622 <u>40,165</u>	2,083,728 20,007 61,376 76,622 40,165
Change in net assets	2,103,735	178,163	2,281,898
Balances, September 30, 2020	19,415,653	6,227,400	25,643,053
Excess of revenues, gains, other support, and nonoperating gains over expenses Change in net unrealized losses on investments Net realized and unrealized gains on investments Net gain on beneficial interests in perpetual trusts Restricted investment income Net assets released from restrictions used for the purchase of property and equipment Change in net assets	9,304,444 (353,437) - - - 67,136 	- 370,284 897,760 26,097 <u>(67,136</u>) <u>1,227,005</u>	9,304,444 (353,437) 370,284 897,760 26,097 - - 10,245,148
Balances, September 30, 2021	\$ <u>28,433,796</u>	\$ <u>7,454,405</u>	\$ <u>35,888,201</u>

The accompanying notes are an integral part of these consolidated financial statements.

Consolidated Statements of Cash Flows

Years Ended September 30, 2021 and 2020

Cash flows from operating activities	<u>2021</u>	<u>2020</u>
Cash flows from operating activities Change in net assets	\$ 10,245,148	\$ 2,281,898
Adjustments to reconcile change in net assets to net cash	φ 10,243,140	φ 2,201,090
provided by operating activities		
Depreciation and amortization	1,791,265	1,871,395
Loss on disposal of equipment	8,088	119,482
Net realized and unrealized gains on investments	•	
Net gain on beneficial interests in perpetual trusts	(4,848,942)	(724,103)
(Increase) decrease in	(897,760)	(76,622)
Patient accounts receivable	20.000	4 400 470
	36,968	1,109,470
Supplies	(99,091)	(78,915)
Prepaid expenses	(39,861)	(11,849)
Other accounts receivable	(208,666)	(35,587)
Increase (decrease) in		(4.40.004)
Accounts payable and accrued expenses	306,861	(146,831)
Accrued salaries and related amounts	(555,476)	251,925
Estimated third-party payor settlements	1,228,855	2,683,453
Medicare accelerated payments	(1,667,166)	8,114,726
PPP refundable advance	(4,020,400)	4,020,400
Other liabilities	(324,658)	210,103
Net cash provided by operating activities	955,165	19,588,945
Cash flows from investing activities		
Purchases of property and equipment	(1,244,648)	(813,253)
Proceeds from sale of property	402	290,802
Proceeds from sale of investments	930,611	2,087,398
Purchases of investments	(5,079,910)	(1,251,026)
Contribution to equity method investee	-	<u>(12,950</u>)
Net cash (used) provided by investing activities	<u>(5,393,545</u>)	300,971
Cash flows from financing activities		
Payments on long-term debt	<u>(330,011</u>)	<u>(319,468</u>)
Net cash used by financing activities	<u>(330,011</u>)	(319,468)
Net (decrease) increase in cash and cash equivalents		
and restricted cash	(4,768,391)	19,570,448
	• • • •	
Cash and cash equivalents and restricted cash, beginning of year	27,317,206	7,746,758
Cash and cash equivalents and restricted cash, end of year	\$ <u>22,548,815</u>	\$ <u>27,317,206</u>
Production of each and each annihilate and restricted each, and of the		
Breakdown of cash and cash equivalents and restricted cash, end of year:	¢ 00 405 547	¢ 06 060 040
Cash and cash equivalents	\$ 22,105,517	\$ 26,969,949
Restricted cash included in assets limited as to use	443,298	<u>347,257</u>
Supplemental each flow information:	\$ <u>22,548,815</u>	\$ <u>27,317,206</u>
Supplemental cash flow information:	¢ E00.004	¢ 600.400
Cash paid for interest	\$ <u>598,861</u>	\$ <u>609,400</u>

The accompanying notes are an integral part of these consolidated financial statements.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

Organization

Valley Regional Healthcare, Inc. (VRHC) and Subsidiary (collectively, the Organization) is a not-forprofit corporation organized under the laws of the State of New Hampshire for the purpose of providing inpatient, outpatient, home health care, and primary care services. VRHC was established as a taxexempt holding company whose purpose is to provide and promote healthcare and health education in the Sullivan County, New Hampshire area. VRHC is the parent company of Valley Regional Hospital, Inc. (VRH or Hospital).

The Organization is a member of the New England Alliance for Health, LLC (NEAH), a limited liability company owned and managed by Mary Hitchcock Memorial Hospital. NEAH makes various services available to the Organization and other members on a contract basis.

1. <u>Summary of Significant Accounting Policies</u>

Principles of Consolidation

The consolidated financial statements of Valley Regional Healthcare, Inc. and Subsidiary represent the activities of the Hospital and VRHC after eliminating all material intercompany balances and transactions.

Basis of Presentation

Net assets and revenues, expenses, gains, and losses are classified based on the existence or absence of donor-imposed restrictions in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic (ASC) 958, *Not-For-Profit Entities*. Under FASB ASC 958 and FASB ASC 954, *Health Care Entities*, all not-for-profit healthcare organizations are required to provide a balance sheet, a statement of operations, a statement of changes in net assets, and a statement of cash flows. FASB ASC 954 requires reporting amounts for an organization's total assets, liabilities, and net assets in a balance sheet; reporting the change in an organization's net assets in statements of operations and changes in net assets; and reporting the change in asset classification:

Net assets without donor restrictions: Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Organization. These net assets may be used at the discretion of the Organization's management and the Board of Trustees (Board).

Net assets with donor restrictions: Net assets subject to stipulations imposed by donors and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Organization or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity.

Donor-restricted contributions are reported as increases in net assets with donor restrictions. When a restriction expires, net assets are reclassified from net assets with donor restrictions to net assets without donor restrictions in the consolidated statements of operations and changes in net assets.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

For purposes of reporting consolidated statements of cash flows, the Organization considers all cash accounts, which are not subject to withdrawal restrictions or penalties, purchased with a maturity of three months or less, as cash and cash equivalents in the accompanying consolidated balance sheets.

Revenue Recognition and Accounts Receivable

Patient service revenue is reported at the amount that reflects the consideration to which the Hospital expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Hospital bills the patients and third-party payors several days after the services are performed or the patient is discharged from the Hospital. Revenue is recognized as performance obligations are satisfied.

The Hospital has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Hospital's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the Hospital does in certain instances enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

Performance obligations are determined based on the nature of the services provided by the Hospital. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The Hospital believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligations based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in hospitals receiving inpatient acute care services or patients receiving services in outpatient centers. The Hospital measures the performance obligation from admission into the hospital or the commencement of an outpatient service to the point when it is no longer required to provide services. Revenue from performance obligations satisfied at a point in time is generally recognized when the goods are provided to patients and customers in a retail setting (for example, cafeteria) and the Hospital does not believe it is required to provide additional goods or services related to that sale.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

Because all of its performance obligations relate to contracts with a duration of less than one year, the Hospital has elected to apply the optional exemption provided in FASB ASC 606-10-50-14 (a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Hospital determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Hospital's policy, and implicit price concessions provided to uninsured patients. The Hospital determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. The Hospital determines its estimate of implicit price concessions based on its historical collection experience with this class of patients and records these as a direct reduction to net patient service revenue. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and changes in commercial contractual terms resulting from contract negotiations and renewals.

Patient accounts receivable are stated at the amount management expects to collect from outstanding balances. Management provides for probable uncollectible amounts through a charge to operations and a credit to a valuation allowance based on its assessment of individual accounts and historical adjustments. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to patient accounts receivable.

The Hospital has contractual agreements with third-party payors that provide for payments to the Hospital at amounts different from its established charges. A summary of the payment arrangements with major third-party payors follows:

Medicare

The Hospital is a Critical Access Hospital and is reimbursed 101% of allowable cost for its inpatient and outpatient services rendered to Medicare beneficiaries. The Hospital is reimbursed for cost reimbursable items at tentative rates, with final settlement determined after submission of annual cost reports by the Hospital and audits thereof by the Medicare fiscal intermediary. The Hospital's Medicare cost reports have been audited by the Medicare fiscal intermediary through September 30, 2016.

<u>Medicaid</u>

Inpatient services rendered to Medicaid program beneficiaries are reimbursed at prospectively determined rates per day of hospitalization. The prospectively determined per-diem rates are not subject to retroactive adjustment. Outpatient services rendered to Medicaid program beneficiaries are reimbursed under a cost reimbursement methodology. The Hospital is reimbursed at a tentative rate with final settlement determined after submission of annual cost reports by the Hospital and audits thereof by the fiscal intermediary. The Hospital's Medicaid cost reports have been audited by the fiscal intermediary through September 30, 2014.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

Medicaid disproportionate share hospital (DSH) payments provide financial assistance to hospitals that serve a large number of low-income patients. The federal government distributes federal DSH funds to each state based on a statutory formula. The states, in turn, distribute their portion of the DSH funding among qualifying hospitals. The states are to use their federal DSH allotments to help cover costs of hospitals that provide care to low-income patients when those costs are not covered by other payors. The State of New Hampshire's distribution of DSH monies to the hospitals is subject to audit by the Centers for Medicare & Medicaid Services (CMS). A number of hospitals in New Hampshire filed a lawsuit relative to the results of the 2011 audit of these DSH payments and the court ruled in favor of the hospitals in March 2016. CMS has appealed the ruling and, until such time as a final ruling from the appeal is made, the Hospital has not changed its position with respect to the amounts recorded in its financial statements. Should the court's ruling stand, the Hospital plans to adjust the amounts held in contingency in the year the ruling is upheld and all avenues for appeal have been exhausted.

Anthem Blue Cross

Radiology and laboratory services are being reimbursed based on a fee schedule. Other inpatient and outpatient services rendered to Anthem Blue Cross subscribers are reimbursed at submitted charges less a negotiated discount. The amounts paid to the Hospital are not subject to any retroactive adjustments.

Other Payors

The Hospital has also entered into payment agreements with certain commercial insurance carriers. The basis for payment to the Hospital under these agreements includes prospectively determined daily rates and discounts from established charges.

Revenue from the Medicare and Medicaid programs accounted for approximately 45% and 17%, respectively, of the Hospital's gross patient revenue for the years ended September 30, 2021 and 2020. Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result of investigations by governmental agencies, various healthcare organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Hospital's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Hospital. In addition, the contracts the Hospital has with commercial and other payors also provide for retroactive audit and review of claims.

Settlements with third-party payors for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Hospital's historical settlement activity, including a determination it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. Adjustments arising from changes in transaction price in 2021 and 2020 increased net patient service revenue by approximately \$859,000 and \$54,000, respectively.

Consistent with the Hospital's mission, care is provided to patients regardless of their ability to pay. Therefore, the Hospital has determined it has provided implicit price concessions to uninsured patients and other uninsured balances (for example, copays and deductibles). The implicit price concessions included in estimating the transaction price represents the difference between amounts billed to patients and the amounts the Hospital expects to collect based on its collection history with those patients.

Patients who meet the Hospital's criteria for charity care are provided care without charge or at amounts less than established rates. Such amounts determined to qualify as charity care are not reported as revenue. The Hospital estimates the costs associated with providing charity care by calculating a ratio of total cost to total gross charges, and then multiplying that ratio by the gross uncompensated charges associated with providing care to patients eligible for free care. The estimated cost of caring for charity care patients was approximately \$420,000 and \$724,000 for 2021 and 2020, respectively.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Hospital also provides services to uninsured patients and offers those uninsured patients a discount, either by policy or law, from standard charges. The Hospital estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions based on historical collection experience. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense. Bad debt expense for the years ended September 30, 2021 and 2020 was not significant.

The Hospital has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the following factors:

- Payors (for example, Medicare, Medicaid, managed care or other insurance, patient) have different reimbursement and payment methodologies
- Length of the patient's service or episode of care
- Method of reimbursement (fee for service or fixed prospective payment)
- Hospital's program that provided the service

For the years ended September 30, 2021 and 2020, the Hospital determined any revenue recognized from goods and services that transfer to the customer at a point in time is not material to the consolidated financial statements.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

<u>Supplies</u>

Supplies are valued using the moving average cost for storeroom and central services supplies and lower of cost (first in, first out) or net realizable value for all other supplies.

Investments and Investment Income

In 2020, the Hospital adopted FASB Accounting Standards Update (ASU) No. 2016-01, *Recognition and Measurement of Financial Assets and Financial Liabilities*. ASU No. 2016-01 requires equity investments to be measured at fair value with changes in fair value recognized in the excess of revenues, gains, other support, and nonoperating gains over expenses unless the income or loss is restricted by donor or law. Unrealized gains and temporary unrealized losses on debt investments are excluded from this measure, and reported as an increase or decrease in net assets without donor restrictions unless the income or loss is restricted by donor or law.

Investments in general are exposed to various risks, such as interest rate, credit, and overall market volatility. As such, it is reasonably possible that changes in the values of investments will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheets.

Assets Limited as to Use

Assets limited as to use primarily consist of assets held by trustees under indenture agreements and designated assets set aside by the Board for future capital improvements, over which the Board retains control and which it may, at its discretion, subsequently use for other purposes such as community service.

In connection with its notes payable to the United States Department of Agriculture-Rural Development Office (USDA-RD) (Note 6), the Organization is required to establish certain reserve and collateral funds.

Donor-Restricted Gifts

Unconditional promises to give cash and other assets to the Organization are reported at fair value at the date the promise is received. Conditional promises to give and indications of intentions to give are reported at fair value at the date the gift is received and the conditions are met. The gifts are reported as support with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified as net assets without donor restrictions and reported in the consolidated statements of operations as net assets released from restrictions.

Donor-restricted endowment gifts are reported as long-term investments or as beneficial interests in perpetual trusts.

Property and Equipment

Property and equipment acquisitions are recorded at cost or, if contributed, at fair market value determined at the date of donation. Depreciation is provided over the estimated useful life of each class of depreciable asset and is computed using the straight-line method.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

Gifts of long-lived assets such as land, buildings, or equipment are reported as support without donor restrictions, and are excluded from the excess of revenues, gains, other support, and nonoperating gains over expenses, unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as support with donor restrictions. Absent explicit donor stipulations about how long those long-lived assets must be maintained, expirations of donor restrictions are reported when the donated or acquired long-lived assets are placed in service.

Coronavirus Aid, Relief, and Economic Security (CARES) Act Provider Relief Stimulus Funds

The CARES Act provided funds to eligible healthcare providers to prevent, prepare for, and respond to the Coronavirus Disease (COVID-19). The funds were appropriated to reimburse healthcare providers for healthcare related expenses or lost revenues that are attributable to COVID-19. The CARES Act provides the U.S. Department of Health and Human Services (HHS) with discretion to operate the program and determine the reporting requirements. During 2020, the Hospital received \$4.931.273 of HHS Provider Relief Stimulus Funds (Funds) and attested to the receipt of the Funds and agreement with the associated terms and conditions. The Hospital has chosen to follow the conditional contribution model for the Funds. At September 30, 2020, the Hospital had recognized \$4,931,273 of the Funds in stimulus revenue in the consolidated statements of operations. Management believes the conditions on which the Funds depend were substantially met. Management believes the position taken is a reasonable interpretation of the rules currently available. Due to the complexity of the reporting requirements and the continued issuance of clarifying guidance, there is at least a reasonable possibility the amount of income recognized related to the lost revenues and qualifying expenses may change by a material amount. Any difference between amounts previously estimated and amounts subsequently determined to be recoverable or payable will be included in income in the year that such amounts become known.

In response to the COVID-19 pandemic, CMS made available an accelerated and advance payment program to Medicare providers. The Hospital received \$8,114,726 of accelerated advanced payments during 2020. Under the program, CMS will begin recouping payment from claims payments one year from the date the respective advances were made to the Hospital.

During 2020, the Hospital qualified for and received a loan pursuant to the Paycheck Protection Program (PPP), a program implemented by the U.S. Small Business Administration (SBA) under the CARES Act, in the amount of \$4,020,400. The PPP provides funds to pay up to 24 weeks of payroll and other specified costs, and forgiveness of the loan is dependent upon compliance with this and other terms and conditions of the CARES Act. During 2021, the Hospital applied for forgiveness under the provisions of the CARES Act and subsequently received the approval of the lending institution and the SBA in June 2021. The Hospital had chosen to follow the conditional contribution model for the loan. The full amount forgiven is reported as PPP refundable advance revenue in the consolidated statement of operations at September 30, 2021. The loan forgiveness is subject to audit by the SBA for a period of six years from the date the loan was forgiven.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

Employee Fringe Benefits

The Hospital has an "earned time" plan which provides benefits to employees for paid leave hours. Under this plan, each employee earns paid leave for each period worked. These hours of paid leave may be used for vacations, holidays, or illnesses. Hours earned, but not used, are vested with the employee. The Hospital accrues a liability for such paid leave as it is earned.

Excess of Revenues, Gains, Other Support, and Nonoperating Gains Over Expenses

The consolidated statements of operations include excess of revenues, gains, other support, and nonoperating gains over expenses. Changes in net assets without donor restrictions which are excluded from this measure, consistent with industry practice, include permanent transfers of assets to and from affiliates for other than goods and services, contributions of long-lived assets (including assets acquired using contributions which by donor restriction were to be used for the purpose of acquiring such assets), net unrealized gains and temporary unrealized losses on investments in debt securities.

Health Insurance

VRHC is partially self-insured with respect to healthcare coverage. This coverage provides medical health benefits to eligible employees and their eligible dependents. Stop loss coverage is in effect which limits the Organization's exposure to loss on an individual basis of \$90,000 (excluding services rendered by the Organization to participants) and an annual aggregate basis of \$1,000,000 (excluding services rendered by the Organization to participants). The Organization estimates an accrual for claims incurred but not reported. Medical insurance expense approximated \$3,896,000 and \$3,079,000 in 2021 and 2020, respectively.

Income Taxes

VRHC and the Hospital are not-for-profit corporations as described in Section 501(c)(3) of the Internal Revenue Code (Code), and are exempt from federal income taxes on related income.

Reclassifications

Certain amounts in the 2020 consolidated financial statements have been reclassified to conform to the current year's presentation.

Subsequent Events

For purposes of the preparation of these consolidated financial statements in conformity with GAAP, management has considered transactions or events occurring through January 19, 2022, the date the September 30, 2021 consolidated financial statements were available to be issued.

In November and December 2021, the Hospital received approximately \$1.2 million and \$1.1 million from the American Rescue Plan Rural Payment distribution and the Provider Relief Fund Phase 4 General distribution, respectively, administered by the Health Resources and Services Administration.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

2. <u>Net Patient Service Revenue</u>

Net patient service revenue consisted of the following for the years ended September 30:

	<u>2021</u>	<u>2020</u>
Patient services Inpatient Outpatient	\$ 9,351,092 <u> 62,139,215</u>	\$ 9,075,257 57,370,562
Gross patient service revenue	71,490,307	66,445,819
Less Medicare and Medicaid allowances Less other contractual allowances Less charity care	20,160,354 8,346,434 <u>621,983</u>	18,178,729 8,471,972 <u>1,073,685</u>
	29,128,771	27,724,386
Net patient service revenue	\$ <u>42,361,536</u>	\$ <u>38,721,433</u>

Each performance obligation is separately identifiable from other promises in the customer contract. As the performance obligations are met (i.e., room, board, ancillary services, level of care), revenue is recognized based upon the allocated transaction price. The transaction price is allocated to separate performance obligations based upon the relative standalone selling price. In instances where management determines there are multiple performance obligations across multiple months, the transaction price is allocated by applying an estimated implicit and explicit rate to gross charges based on the separate performance obligations.

In assessing collectibility, the Hospital has elected the portfolio approach. This portfolio approach is being used as the Hospital has a large volume of similar contracts with similar classes of customers. The Hospital reasonably expects that the effect of applying a portfolio approach to a group of contracts would not differ materially from considering each contract separately. Management's judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. As a result, aggregating all of the contracts (which are at the patient level) by the particular payor or group of payors, will result in the recognition of the same amount of revenue as applying the analysis at the individual patient level.

Net patient service revenue recognized for the years ended September 30, 2021 and 2020 from these major payors is as follows:

	<u>2021</u>	<u>2020</u>
Medicare and Medicaid	\$ 26,470,554	\$ 25,131,066
Commercial	14,184,556	12,576,762
Self-pay	1,706,426	1,013,605
Total	\$ <u>42,361,536</u>	\$ <u>38,721,433</u>

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

3. Availability and Liquidity of Financial Assets

As of September 30, 2021 and 2020, the Organization has working capital of \$12,633,739 and \$12,163,062, respectively, and average days (based on normal expenditures, excluding depreciation and amortization) cash and cash equivalents on hand of 174 and 229, respectively.

The Organization's goal is to maintain financial assets to meet 45 days of operating expenses (\$5,732,254 and \$5,292,983 at September 30, 2021 and 2020, respectively). The annual operating budget is determined with the goal of generating sufficient net patient service revenue and cash flows to allow the Organization to be sustainable to support its mission and vision.

Financial assets and liquidity resources available within one year for general expenditure, such as operating expenses, scheduled principal payments on debt, and capital construction costs not financed with debt, were as follows as of September 30:

	<u>2021</u>	<u>2020</u>
Cash and cash equivalents Short-term investments Patient accounts receivable, net Other accounts receivable	\$ 22,105,517 152,584 4,048,637 <u>1,562,297</u>	\$26,969,949 149,218 4,085,605 <u>1,353,631</u>
Financial assets available to meet cash needs for general expenditures within one year	\$ <u>27,869,035</u>	\$ <u>32,558,403</u>

At September 30, 2021 and 2020, cash and cash equivalents included \$6,447,560 and \$8,114,276, respectively, specifically related to Medicare Accelerated Payments. This represents 50 and 69 days of cash and cash equivalents on hand, respectively.

The Organization has assets limited as to use of \$23,393,340 and \$19,013,030 at September 30, 2021 and 2020, respectively, that are designated assets set aside by the Board primarily for future capital improvements and community service. These assets limited as to use are not available for general expenditure within the next year; however, the internally designated amounts could be made available, if necessary.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

4. Investments and Fair Value Measurement

Assets Limited as to Use

The composition of assets limited at to use at September 30, 2021 and 2020 is set forth in the following table. Investments are stated at fair value.

	<u>2021</u>	<u>2020</u>
Internally designated for capital acquisitions and community service: Cash and short-term investments	\$ 763,380	\$ 69,293
Corporate bonds	\$	
Marketable equity securities	17,616,935	
Fixed income mutual funds	3,462,669	<u>5,129,932</u>
	23,393,340	<u>19,013,030</u>
Cash with donor restrictions	3,077	3,077
Limited under loan agreement:		
Cash and cash equivalents	440,221	344,180
Treasury obligations and government securities	<u>5,341,921</u>	5,403,725
	5,782,142	5,747,905
	\$ <u>29,178,559</u>	\$ <u>24,764,012</u>
Other Investments		
Other investments consisted of the following as of September 30:		
	<u>2021</u>	<u>2020</u>
Short-term investments Cash equivalents	\$ 146,613	\$ 143,247
Marketable equity securities	5,971	φ 143,247 5,971
Long term investmente	152,584	149,218
Long-term investments Cash equivalents	140,646	77,819
Certificates of deposit	3,642,714	-
Corporate bonds	276,355	177,824
Marketable equity securities Fixed income mutual funds	4,636,507 <u>928,006</u>	3,526,980 <u>1,165,236</u>
	320,000	1,103,230
	9,624,228	4,947,859
	\$ <u>9,776,812</u>	\$ <u>5,097,077</u>

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

Investment income and gains (losses) on investments are comprised of the following:

Net assets without donor restrictions:	<u>2021</u>	<u>2020</u>
Interest and dividend income Realized gains (losses) on sales of securities Investment management fees	\$ 746,266 433,276 <u>(178,082</u>)	\$ 806,153 (124,672) (161,110)
	\$ <u>1,001,460</u>	\$ <u>520,371</u>
Other changes in net assets:		
Net unrealized gains without donor restrictions Donor restricted investment income Donor restricted net realized and unrealized	\$ 4,045,382 26,097	\$ 787,399 40,165
gains	370,284	61,376
	\$ <u>4,441,763</u>	\$ <u>888,940</u>

In the opinion of management, no individual unrealized loss as of September 30, 2021 represents an other-than-temporary impairment. Individual holdings in an unrealized loss position as of September 30, 2021 and 2020 totaled \$195,713 and \$985,248, respectively.

Endowment

Changes in endowment (with donor restrictions) net assets are as follows:

	<u>Net Assets with Donor Restrictions</u> Accumulated Appreciation of Funds of					
	Funds of Perpetual Duration	Perpetual <u>Duration</u>	<u>Total</u>			
Balances, September 30, 2019	\$ <u>1,498,106</u>	\$ <u>4,396,994</u>	\$ <u>5,895,100</u>			
Investment income Net appreciation/change in perpetual trusts Total investment return	25,304 <u>61,376</u> 86,680	<u>76,622</u> 76,622	25,304 <u>137,998</u> 163,302			
Net change	86,680	76,622	163,302			
Balances, September 30, 2020	1,584,786	4,473,616	6,058,402			
Investment income Net appreciation/change in perpetual trusts Total investment return	19,849 <u>370,284</u> 390,133	<u>897,760</u> 897,760	19,849 <u>1,268,044</u> 1,287,893			
Expenditures	(67,136)		(67,136)			
Net change	322,997	897,760	1,220,757			
Balances, September 30, 2021	\$ <u>1,907,783</u>	\$ <u>5,371,376</u>	\$ <u>7,279,159</u>			

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

The Organization has interpreted the State of New Hampshire Uniform Prudent Management of Institutional Funds Act (UPMIFA) such that the Board is allowed to appropriate for expenditure for the uses and purposes for which the endowment fund is established, unless otherwise specified by the donor, so much of the net appreciation, realized and unrealized, in the fair value of the assets of the endowment fund over the historic dollar value of the fund, as is prudent. In so doing, the Board must consider the long-term and short-term needs of the Organization in carrying out its purpose, its present and anticipated financial requirements, expected total return on its investments, price-level trends, and general economic conditions. As a result of this interpretation, the Organization classifies as net assets with perpetual donor restriction (a) the original value of the gifts donated to the perpetual endowment when explicit donor stipulations requiring perpetual maintenance of the historical fair value are present, and (b) the original value of the subsequent gifts to be maintained in perpetuity when explicit donor stipulations requiring perpetual maintenance of the historical fair value are present. The remaining portion of the donor restricted endowment fund composed of accumulated gains not required to be maintained in perpetuity is classified as net assets with donor restrictions temporary in nature until those amounts are appropriated for expenditure in a manner consistent with the donor's stipulations. The Board approves amounts to be appropriated from time to time, based on the Organization's needs and the provisions of UPMIFA.

The long-term investment objective of the Organization's endowment funds is to honor the restricted purposes of donors' gifts, achieve a proper balance between the Organization's present and future needs, and to provide the Organization with a source of current revenue as well as providing for a perpetual, growing, and consistent source of revenue over the long-term.

To accomplish this objective, funds are to be invested for growth of principal and income for protection against inflation. The goal is to achieve a total return, net of investment management and administrative fees, which should exceed the Balanced Growth Index plus 2% annually. This goal is designed to optimize prudent risk so as to protect and increase the purchasing power of the invested assets, while providing income. It is recognized that this goal may be easily achieved in some periods, while more difficult to achieve in other periods.

To accomplish its investment objectives and to control risk, the Organization's policy is that its portfolio will be diversified across multiple asset classes as follows:

<u>Asset Class</u>	<u>Range</u>
Cash Equivalents	0% - 25%
Domestic Equities	60% - 85%
Domestic Fixed Income (including preferred stock)	15% - 30%

From time to time, the fair value of assets associated with donor-restricted endowment funds may fall below the level of the donors' original gift(s) ("underwater"). To retain the original value of the underwater donor-restricted funds, any deficiencies would be reported as net assets without donor restrictions. Subsequent gains that would restore the fair value of the underwater endowment funds to their required level would be classified as an increase in net assets without donor restrictions. The Board at times may continue to appropriate from underwater endowment funds for certain programs deemed prudent by the Board. There were no deficiencies of this nature that are reported in net assets with donor restrictions as of September 30, 2021 and 2020.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

Fair Value Measurement

FASB ASC 820, *Fair Value Measurement*, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date.

Level 2: Significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, and other inputs that are observable or can be corroborated by observable market data.

Level 3: Significant unobservable inputs that reflect an entity's own assumptions about the assumptions that market participants would use in pricing an asset or liability.

		Fair Value M	eas	urements at	Se	ptember 30.	, 20	21, Using
		Total		Level 1		Level 2		Level 3
Assets:								
Cash and cash equivalents	\$	1,493,937	\$	1,493,937	\$	-	\$	-
Certificates of deposit		3,642,714		3,642,714		· · · ·		-
Corporate bonds		1,826,711		-		1,826,711		-
Marketable equity securities Treasury obligations and		22,259,413		22,259,413		-		-
government securities		5,341,921		5,341,921		-		-
Fixed income mutual funds		4,390,675		4,390,675		-		-
Beneficial interests in perpetual trusts		<u>5,117,482</u>		-	_	-	_	5,117,482
Total assets	\$ <u>_</u>	44,072,853	\$ <u></u>	37,128,660	\$_	1,826,711	\$_	5,117,482
		Fair Value M	Лea	surements at	Se	ptember 30.	202	20. Usina
		Total		Level 1		Level 2		Level 3
Assets:								
Cash and cash equivalents	\$	637,616	\$	637,616	\$	-	\$	-
Corporate bonds		632,030		-		632,030		-
Marketable equity securities		16,892,550		16,892,550		-		-
Treasury obligations and								
government securities		5,403,725		5,403,725		-		-
Fixed income mutual funds		6,295,168		6,295,168		-		-
Beneficial interests in perpetual trusts	-	4,219,722		-	-	-	-	4,219,722
Total assets	\$_	34,080,811	\$	29,229,059	\$_	632,030	\$_	4,219,722

Assets measured at fair value on a recurring basis are summarized below:

The fair value for Level 2 assets is primarily based on quoted market prices of underlying assets, comparable securities, interest rates, and credit risk. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly,

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

the fair value estimates may not be realized in an immediate settlement of the instrument. The fair value of Level 3 assets is based on the quoted market prices of the underlying assets, but these assets are classified as Level 3 as there is no market in which to trade the beneficial interest itself. The following is a reconciliation of assets in which significant unobservable inputs (Level 3) were used in determining fair value:

Balance, September 30, 2019	\$ 4,143,100
Change in value of trusts	76,622
Balance, September 30, 2020	4,219,722
Change in value of trusts	<u> </u>
Balance, September 30, 2021	\$ <u>5,117,482</u>

Investment in Summercrest

VRHC owned a 37% interest in Summercrest Assisted Living, LLC (Summercrest) as of September 30, 2021 and 2020. Summercrest, a long-term care entity in Newport, New Hampshire, opened for operations on March 1, 1998. Summercrest's fiscal year-end is December 31.

The investment in Summercrest is reported in accordance with the equity method, including VRHC's applicable share of the profit or loss based on the financial statement information of Summercrest for the twelve months ended each September 30. No equity distributions were received during the years ended September 30, 2021 and 2020. VRHC made a capital contribution in the amount of \$12,950 in 2020.

5. Property and Equipment

A summary of property and equipment follows:

\$ 1,297,450	\$ 1,297,450
17,133,930	17,125,899
14,700,750	14,694,537
15,178,926	14,549,929
<u>1,144,107</u>	855,760
49,455,163	48,523,575
<u>37,574,538</u>	<u>36,097,473</u>
\$ 11.880.625	\$ <u>12,426,102</u>
	14,700,750 15,178,926 <u>1,144,107</u> 49,455,163

Depreciation expense for the years ended September 30, 2021 and 2020 was \$1,781,635 and \$1,861,764, respectively.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

6. Borrowings

Long-Term Debt

A summary of long-term debt follows:

Mortgage notes payable due to USDA-RD in monthly installments of \$77,406, including interest, through January 2053. Interest is fixed at 3.25%. Collateralized	2021	2020
by real property and investments.	\$ 18,240,590	\$ 18,570,601
Less: unamortized debt issuance costs	301,746	311,376
Total long-term debt Less current portion	17,938,844 <u>340,902</u>	18,259,225 <u>330,011</u>
Long-term debt, excluding current portion	\$ <u>17,597,942</u>	\$ <u>17,929,214</u>

Scheduled principal repayments on long-term debt are as follows:

Year ending September 30,		
2022	\$ 340,90)2
2023	352,15	51
2024	363,77	'2
2025	375,77	'7
2026	388,17	'7
Thereafter	<u> 16,419,81</u>	1

\$<u>18,240,590</u>

2021

2020

In September 2017, VRHC was awarded a \$19,400,000 Community Facility Loan through the USDA-RD. The proceeds of the loan and a required contribution from VRHC of \$5.5 million were used to purchase certain land and buildings from the Hospital. The Hospital subsequently refunded its outstanding Series 2008 Revenue Bonds. The Organization was also required to place an additional \$5 million in a reserve account as collateral for this loan.

The mortgage note agreements with the USDA-RD require VRHC to fund monthly payments into a cash reserve account until a balance of \$928,872 is reached. VRHC continues to fund this reserve account. The reserve may be used for unforeseen damages, approved improvements to property or monthly loan payments when approved. At September 30, 2021 and 2020, the balance was \$364,803 and \$271,573, respectively.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

7. Net Assets with Donor Restrictions

Net assets with donor restrictions are available for the following purposes at September 30:

Funds with donor restrictions temporary in nature Endowment accumulated earnings to support	<u>2021</u>	<u>2020</u>
healthcare services Purchase of equipment, health education, and	\$ 1,907,783	\$ 1,584,786
indigent care	175,246	<u> 168,998</u>
Funds maintained in perpetuity, the income from	2,083,029	1,753,784
which is expendable to support healthcare services	<u>5,371,376</u>	4,473,616
Total net assets with donor restrictions	\$ <u>7,454,405</u>	\$ <u>6,227,400</u>

8. Concentrations of Credit Risk

The Hospital is located in Claremont, New Hampshire. The Hospital grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of receivables from patients and third-party payors was as follows:

	<u>2021</u>	<u>2020</u>
Medicare	34%	32%
Medicaid	14	12
Anthem Blue Cross	10	10
Other third-party payors	14	17
Patients	28	29
	<u>100</u> %	<u>100</u> %

The Organization routinely invests its surplus operating funds in money market mutual funds. These funds generally invest in highly liquid U.S. government and agency obligations. Investments in money market funds are not insured or guaranteed by the U.S. government.

The Organization maintains its cash in bank deposit and other accounts which, at times, may exceed federally insured limits. The Organization has not experienced any losses in such accounts. Management believes the Organization is not exposed to any significant risk on cash and cash equivalents.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

9. <u>Commitments and Contingencies</u>

The Organization insures its comprehensive general liability and professional liability exposures on a claims-made basis, including prior acts coverage, with another commercial carrier. This coverage is provided by primary and excess insurance policies subject to shared policy limits with other selected NEAH entities. The policies are renewable on an annual basis and have been renewed through September 30, 2021. The Organization is subject to complaints, claims, and litigation due to potential claims which arise in the normal course of business. FASB ASC 954-450, *Health Care Entities – Contingencies*, provides clarification to companies in the healthcare industry on the accounting for professional liability and similar insurance. ASC 954-450 states that insurance liabilities should not be presented net of insurance recoveries and that an insurance receivable should be recognized on the same basis as the liabilities, subject to the need for a valuation allowance for uncollectible accounts. The Organization has evaluated its exposure to losses arising from potential claims and has properly accounted for them in the consolidated balance sheets for the years ended September 30, 2021 and 2020.

Operating Leases

The Hospital leases equipment and buildings under various operating lease agreements. Total lease expense for the years ended September 30, 2021 and 2020 was \$495,371 and \$497,351, respectively.

The following is a schedule of future minimum lease payments required under operating leases:

Year ending September 30,		
2022	\$	233,500
2023		46,500
2024		45,000
2025	-	45,000
	\$_	370,000

10. Savings and Retirement Plan

The Hospital participates in a tax-sheltered annuity plan which was adopted under Section 403(b) of the Code for eligible employees of the Hospital. Under the plan, employees make elective deferrals as allowed under Internal Revenue Service regulations. The Hospital, at its discretion, matches each participating employee contribution up to 3% of annual compensation. The plan expense for the year ended September 30, 2021 and 2020 was \$135,100 and \$1,460, respectively. Effective October 1, 2019, the Hospital ceased matching contributions to the plan.

11. Beneficial Interests in Perpetual Trusts

The Hospital is the beneficiary of three trusts, a portion of the income from which is to be paid to the Hospital in perpetuity. VRH's interest in the trusts is recognized as an asset at the fair value of VRH's percentage of the underlying assets, which totaled \$5,117,482 and \$4,219,722 as of September 30, 2021 and 2020, respectively. Increases and decreases in the carrying value of this asset are included in net assets with donor restrictions. Distributions from these trusts totaled \$141,822 and \$151,539 for the years ended September 30, 2021 and 2020, respectively.

Notes to Consolidated Financial Statements

September 30, 2021 and 2020

12. Related Party Transactions

The Hospital leases certain real property and buildings from, and contracts for management services with, VRHC. The Hospital recorded \$2,011,734 and \$1,918,208 in lease and management services expenses and VRHC recognized other operating revenue of the same in 2021 and 2020, respectively. These transactions have been eliminated in the consolidation.

13. Functional Expenses

The financial statements report certain categories of expenses that are attributable to more than one program or support function. Therefore, these expenses require an allocation on a reasonable basis that is consistently applied. Employee benefits are allocated based on salaries and occupancy costs are allocated by square footage. Expenses related to these functions were as follows for the years ended September 30:

<u>2021</u>	Healthcare <u>Services</u>	Support <u>Services</u>	<u>Total</u>
Salaries Employee benefits Professional fees Supplies and other Insurance Depreciation and amortization Interest Medicaid enhancement tax	\$ 17,702,587 4,850,085 5,034,029 10,157,952 1,635 1,526,428 - 2,019,557	\$ 2,249,594 604,184 368,449 2,091,060 816,954 264,837 598,861	\$ 19,952,181 5,454,269 5,402,478 12,249,012 818,589 1,791,265 598,861 2,019,557
	\$ <u>41,292,273</u>	\$ <u>6,993,939</u>	\$ <u>48,286,212</u>
2020	Healthcare <u>Services</u>	Support <u>Services</u>	<u>Total</u>
Salaries Employee benefits Professional fees Supplies and other Insurance Depreciation and amortization Interest Medicaid enhancement tax	\$ 17,182,192 3,982,762 4,029,115 9,697,394 4,308 1,578,816 - 2,052,579 \$ 38 527 166	\$ 2,228,749 542,350 294,898 1,885,279 422,946 292,579 609,400 -	<pre>\$ 19,410,941 4,525,112 4,324,013 11,582,673 427,254 1,871,395 609,400 2,052,579</pre>
	\$ <u>38,527,166</u>	\$ <u>6,276,201</u>	\$ <u>44,803,367</u>

Schedule 1

Consolidating Balance Sheets

September 30, 2021 (With Comparative Totals for September 30, 2020)

ASSETS

Current assets	<u>VRHC</u>		<u>VRH</u>	<u>E</u>	<u>iminations</u>	<u>c</u>	2021 Consolidated	2020 <u>Consolidated</u>
Cash and cash equivalents	\$ 715,776	\$	21,389,741	\$	-	\$	22,105,517	\$ 26,969,949
Short-term investments	-		152,584		-		152,584	149,218
Patient accounts receivable, net	-		4,048,637		-		4,048,637	4,085,605
Due from affiliates	38,866		459,977		498,843		-	-
Supplies	-		1,025,989		-		1,025,989	926,898
Prepaid expenses	22,622		376,677		-		399,299	359,438
Other accounts receivable	 84,065	_	2,073,232				2,157,297	1,948,631
Total current assets	 861,329	_	29,526,837		498,843	_	29,889,323	34,439,739
Assets limited as to use			00 000 0 40				~~~~~	40.040.000
Internally designated for capital acquisitions and community service	-		23,393,340		-		23,393,340	19,013,030
By loan agreement	364,803		5,417,339		-		5,782,142	5,747,905
Cash with donor restrictions	 3,077	_	-		-		3,077	3,077
Total assets limited as to use	 367,880	_	28,810,679			_	29,178,559	24,764,012
Property and equipment, net	8,395,225		3,485,400		-		11,880,625	12,426,102
Long-term investments	3,821,487		5,802,741		-		9,624,228	4,947,859
Beneficial interests in perpetual trusts	 -	_	5,117,482	_		_	5,117,482	4,219,722
Total assets	\$ 13,445,921	\$_	72,743,139	\$	498,843	\$_	85,690,217	\$ <u>80,797,434</u>

Consolidating Balance Sheets

September 30, 2021 (With Comparative Totals for September 30, 2020)

LIABILITIES AND NET ASSETS (DEFICIT)

Current liabilities		<u>VRHC</u>	<u>VRH</u>	Eliminations	2021 <u>Consolidated</u>	2020 <u>Consolidated</u>
Current portion of long-term debt Accounts payable and accrued expenses Accrued compensated absences Accrued salaries and related amounts Estimated third-party payor settlements Due to affiliates Medicare accelerated payments PPP refundable advance Deferred revenue Other current liabilities	\$	340,902 130,332 23,568 9,958 - 463,477 - 117,027 2,029	\$	\$ - - - - 498,843 - - - - -	\$ 340,902 3,316,629 1,202,385 479,640 4,437,080 - 6,447,560 - 268,087 763,301	\$ 330,011 3,009,768 1,204,357 1,033,144 3,208,225 - 8,114,726 4,020,400 530,162 825,884
Total current liabilities		1,087,293	16,667,134	498,843	17,255,584	22,276,677
Long-term debt, excluding current portion		17,597,942	-	-	17,597,942	17,929,214
Estimated third-party payor settlements, excluding current portion	_		14,948,490		14,948,490	14,948,490
Total liabilities	_	18,685,235	31,615,624	498,843	49,802,016	55,154,381
Net assets (deficit) Without donor restrictions With donor restrictions	_	(5,239,390) <u>76</u>	33,673,186 <u>7,454,329</u>		28,433,796 7,454,405	19,415,653 <u>6,227,400</u>
Total net assets (deficit)		(5,239,314)	41,127,515		35,888,201	25,643,053
Total liabilities and net assets (deficit)	\$	13,445,921	\$ <u>72,743,139</u>	\$ <u>498,843</u>	\$ <u>85,690,217</u>	\$ <u>80,797,434</u>

Consolidating Statements of Operations

Year Ended September 30, 2021 (With Comparative Totals for Year Ended September 30, 2020)

		VRHC	VRH	Eliminations	2021 <u>Consolidated</u>	2020 <u>Consolidated</u>
Revenues, gains, and other support without donor restrictions Net patient service revenue	\$	-	\$ 42,361,536	\$ -	\$ 42,361,536	\$ 38,721,433
Other revenues Medicaid DSH direct payment revenue HHS stimulus revenue PPP refundable advance revenue Grant revenue Total revenues, gains, and other support	=	2,105,050 - - 2,105,050	1,210,873 3,802,644 - 4,020,400 <u>707,895</u> 52,103,348	2,011,734 - - - - 2,011,734	1,304,189 3,802,644 - 4,020,400 <u>707,895</u> 52,196,664	1,590,419 - 4,931,273 <u>360,781</u> 45,603,906
Expenses Salaries Employee benefits Professional fees Supplies and other Insurance Depreciation and amortization Interest Medicaid enhancement tax Total expenses Operating (loss) income		284,355 50,034 491,348 264,674 37,138 1,231,332 598,861 - - 2,957,742 (852,692)	19,667,826 5,404,235 4,911,130 13,996,072 781,451 559,933 - - 2,019,557 47,340,204 4,763,144	2,011,734 - - - - - - - - - - - - - - - - - - -	19,952,181 5,454,269 5,402,478 12,249,012 818,589 1,791,265 598,861 2,019,557 48,286,212 3,910,452	19,410,941 4,525,112 4,324,013 11,582,673 427,254 1,871,395 609,400 2,052,579 44,803,367 800,539
Nonoperating gains (losses) Investment income Change in net unrealized gains on equity investments Other nonoperating (losses) gains, net Nonoperating gains, net	=	141,646 623,064 764,710	859,814 3,775,755 (6,287) 4,629,282	- - 	1,001,460 4,398,819 (6,287) 5,393,992	520,371 767,392 (4,574) 1,283,189
(Deficiency) excess of revenues, gains, other support, and nonoperating gains over expenses		(87,982)	9,392,426	-	9,304,444	2,083,728
Change in net unrealized (losses) gains on investments Net assets released from restrictions used for the purchase of property and equipment	_	(70,692)	(282,745) <u>67,136</u>	-	(353,437) <u>67,136</u>	20,007
Change in net assets without donor restrictions	\$	(158,674)	\$ <u>9,176,817</u>	\$ <u> </u>	\$ <u>9,018,143</u>	\$ <u>2,103,735</u>



INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF CONSOLIDATED FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

Board of Trustees Valley Regional Healthcare, Inc.

We have audited, in accordance with U.S generally accepted auditing standards and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Valley Regional Healthcare, Inc. and Subsidiary (Organization), which comprise the consolidated balance sheet as of September 30, 2021, and the related consolidated statements of operations, changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated January 19, 2022. Our report on the consolidated financial statements contained an unmodified opinion.

Internal Control over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the Organization's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, we do not express an opinion on the effectiveness of the Organization's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the Organizations' consolidated financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that have not been identified. We did identify certain deficiencies in internal control, described in the accompanying schedule of findings and questioned costs as items 2021-001 and 2021-002, that we consider to be material weaknesses.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Organization's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results

Board of Trustees Valley Regional Healthcare, Inc.

of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Organization's Responses to Findings

The Organization's responses to the findings identified in our audit is described in the accompanying schedule of findings and questioned costs. The Organization's responses were not subjected to the auditing procedures applied in the audit of the consolidated financial statements and, accordingly, we express no opinion on them.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Organization's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Organization's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Berry Dunn Mcneil & Parker, LLC

Manchester, New Hampshire January 19, 2022



INDEPENDENT AUDITOR'S REPORT ON COMPLIANCE FOR THE MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE

Board of Trustees Valley Regional Healthcare, Inc.

Report on Compliance for the Major Federal Program

We have audited Valley Regional Healthcare, Inc. and Subsidiary's (Organization) compliance with the types of compliance requirements described in the Office of Management and Budget *Compliance Supplement* that could have a direct and material effect on the Organization's major federal program for the year ended September 30, 2021. The Organization's major federal program is identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance for the Organization's' major federal program based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with U.S. generally accepted auditing standards; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the Organization's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for the major federal program. However, our audit does not provide a legal determination of the Organization's compliance.

Opinion on the Major Federal Program

In our opinion, the Organization complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended September 30, 2021.

Report on Internal Control over Compliance

Management of the Organization is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the Organization's internal control over compliance with the types of

requirements that could have a direct and material effect on the major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for the major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the Organization's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance is control over compliance with a type of compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the consolidated financial statements of the Organization as of and for the year ended September 30, 2021, and have issued our report thereon dated January 19, 2022, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with U.S. generally accepted auditing standards. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Berry Dunn McNeil & Parker, LLC

Manchester, New Hampshire January 19, 2022

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2021

Federal Grantor/Pass-Through <u>Grantor/Program Title</u>	Federal AL <u>Number</u>	Pass-Through Grantor/ Agreement <u>Number</u>	Federal <u>Expenditures</u>
United States (U.S) Department of Treasury			
Pass-through: State of New Hampshire Department of Health and Human Services COVID-19 Coronavirus Relief Fund COVID-19 Coronavirus Relief Fund	21.019 21.019	N/A N/A	\$ 29,000 5,783
Total U.S. Department of Treasury			34,783
U.S. Department of Health and Human Services			
Direct: COVID-19 Provider Relief Fund	93.498	N/A	4,931,273
Pass-through: Foundation for Healthy Communities			
COVID-19 Epidemiology and Laboratory Capacity for Prevention Infectious Diseases (ELC) National Bioterrorism Hospital Preparedness Program Small Rural Hospital Improvement Grant Program	93.323 93.889 93.301	05-095-090- 903010- 19010000 N/A N/A	303,516 1,940 56,711
Mary Hitchcock Memorial Hospital Medicaid Cluster Medical Assistance Program	93.778	N/A	120,420
Total U.S. Department of Health and Human Services			5,413,860
Total Expenditures of Federal Awards			\$ <u>5,448,643</u>
Organizations included in this Schedule are:			

Organizations included in this Schedule are: Valley Regional Hospital – EIN 02-0222118

Notes to Schedule of Expenditures of Federal Awards

Year Ended September 30, 2021

Notes to Schedule of Expenditures of Federal Awards

1. Basis of Presentation

The accompanying schedule of expenditures of federal awards (Schedule) includes the federal grant activity of Valley Regional Healthcare, Inc. and Subsidiary (Organization) under programs of the federal government for the year ended September 30, 2021. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of the Organization, it is not intended to and does not present the consolidated financial position, changes in net assets or cash flows of the Organization.

2. Summary of Significant Accounting Policies

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement.

The Organization has elected not to use the 10% de minimis indirect cost rate.

Schedule of Findings and Questioned Costs

Year Ended September 30, 2021

1. <u>Summary of Auditors' Results</u>

General-purpose basic consolidated financial statements

Type of auditors' report issued: Internal control over financial reporting:		Unmo	odified	
Material weakness(e's) identified?		Х	_yes	no
Reportable condition(s) identified no considered to be material weakne			_yes	X none reported
Noncompliance material to general-pur basic consolidated financial stateme			_yes	<u>X</u> no
Federal Awards				
Internal control over major program: Material weakness(e's) identified?	not		_ yes	<u>X</u> no
Significant deficiency(ies) identified considered to be material weakne			_yes	<u>X</u> none reported
Type of auditor's report issued on comp for major program:	bliance	Unmo	odified	
Any audit findings disclosed that are re to be reported in accordance with 2 Section 200.516(a)?			_yes	<u>X</u> no
Identification of major program:				
<u>AL Number(s)</u>	Name of Federal Pro	gram c	or Cluster	
93.498	COVID-19 - Provider	Relief	Fund	
Dollar threshold used to distinguish between Type A and Type B program	ms:	\$750,	000	
Auditee qualified as low-risk auditee?			yes	<u>X</u> no

Schedule of Findings and Questioned Costs (Continued)

Year Ended December 31, 2021

2. <u>Consolidated Financial Statement Findings</u>

Finding 2021-001

Criteria:

Management is responsible for the design, implementation, and maintenance of effective internal control over financial reporting that provides reasonable assurance the internal control will prevent misstatements, intentional or unintentional, from occurring, or detect and correct misstatements on a timely basis. Additionally, the Organization is responsible for maintaining complete and accurate financial records.

Condition:

The information entered by the Organization into the Provider Relief Funds Portal (Portal) was inadvertently summarized and was not identified during subsequent review.

Cause:

The federal program is a new program as a result of the COVID-19 pandemic and, due to multiple priorities, management did not identify the incorrect information during subsequent review.

Effect:

The Organization did not report the correct fiscal year 2020 budgeted amounts for quarter 4 of 2020 and quarters 1 and 2 of 2021. As a result of the spreadsheet error, total lost revenue reported during the submission on the Portal was \$624,229 higher than actually incurred.

Recommendation:

We recommend management review the current system for any future submissions, placing higher scrutiny on the source documentation of the information being reported.

Management's Response:

Management has reviewed the finding and will evaluate the current internal control processes and systems for future reporting submissions.

Schedule of Findings and Questioned Costs (Concluded)

Year Ended December 31, 2021

Finding 2021-002

Criteria:

Management is responsible for the design, implementation, and maintenance of effective internal control over financial reporting that provides reasonable assurance the internal control will prevent misstatements, intentional or unintentional, from occurring, or detect and correct misstatements on a timely basis. Additionally, the Organization is responsible for maintaining complete and accurate financial records.

Condition:

The information entered by the Organization into the Provider Relief Funds Portal (Portal) was inadvertently summarized and was not identified during subsequent review.

Cause:

The federal program is a new program as a result of the COVID-19 pandemic and, due to multiple priorities, management did not identify the incorrect information during subsequent review.

Effect:

The Organization did not include the impact of prior year third-party payor settlements in net patient service revenue for Period 1 reporting. As a result of the error, total lost revenue reported during the submission on the Portal was \$680,029 higher than actually incurred.

Recommendation:

We recommend management review the current system for any future submissions, placing higher scrutiny on the reporting guidance for the information being reported.

Management's Response:

Management has reviewed the finding and will evaluate the current internal control processes and systems for future reporting submissions.

3. Federal Award Findings and Questioned Costs

None.

Summary Schedule of Prior Year Findings and Questioned Costs

Year Ended September 30, 2021

Not applicable.

Dartmouth-Hitchcock Health and Subsidiaries

Consolidated Financial Statements June 30, 2022 and 2021

Dartmouth-Hitchcock Health and Subsidiaries Index June 30, 2022 and 2021

Page(s)

Report of Independent Auditors	1–2
Consolidated Financial Statements	
Balance Sheets	3
Statements of Operations and Changes in Net Assets	4–5
Statements of Cash Flows	6
Notes to Financial Statements	7–49
Consolidating Supplemental Information	
Balance Sheets	51–54
Statements of Operations and Changes in Net Assets without Donor Restrictions	55–58



Report of Independent Auditors

To the Board of Trustees of Dartmouth-Hitchcock Health and subsidiaries

Opinion

We have audited the accompanying consolidated financial statements of Dartmouth-Hitchcock Health and its subsidiaries (the "Health System"), which comprise the consolidated balance sheets as of June 30, 2022 and 2021, and the related consolidated statements of operations and changes in net assets and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Health System as of June 30, 2022 and 2021, and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Health System and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Health System's ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

PricewaterhouseCoopers LLP, 101 Seaport Boulevard, Suite 500, Boston, MA 02210 T: (617) 530 5000, F: (617) 530 5001, www.pwc.com/us



In performing an audit in accordance with US GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Health System's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Health System's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements taken as a whole. The accompanying consolidating information as of and for the years ended June 30, 2022 and 2021 is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The consolidated financial statements and certain additional procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the consolidating information is fairly stated, in all material respects, in relation to the consolidated financial statements rather than to present the financial position, results of operations and cash flows of the individual companies and is not a required part of the consolidated financial statements. Accordingly, we do not express an opinion on the financial position, results of operations and cash flows of the individual companies.

Vicenaterhorse Coopers UP

Boston, Massachusetts November 16, 2022

Dartmouth-Hitchcock Health and Subsidiaries Consolidated Balance Sheets June 30, 2022 and 2021

(in thousands of dollars)		<u>2022</u>		<u>2021</u>
Assets Current assets				
Cash and cash equivalents	\$	191,929	\$	374,928
Patient accounts receivable, net (Note 4)		251,250		232,161
Prepaid expenses and other current assets		169,133		157,318
Total current assets		612,312		764,407
Assets limited as to use (Notes 5 and 7)		1,181,094		1,378,479
Other investments for restricted activities (Notes 5 and 7) Property, plant, and equipment, net (Note 6)		175,116 764,840		168,035 680,433
Right-of-use assets, net (Note 16)		58,925		58,410
Other assets		172,163		177,098
Total assets	\$	2,964,450	\$	3,226,862
Liabilities and Net Assets				
Current liabilities	•		•	o 407
Current portion of long-term debt (Note 10) Current portion of right-of-use obligations (Note 16)	\$	6,596 11,319	\$	9,407 11,289
Current portion of liability for pension and other postretirement		11,319		11,209
plan benefits (Note 11)		3,500		3,468
Accounts payable and accrued expenses		156,572		131,224
Accrued compensation and related benefits		190,560		182,070
Estimated third-party settlements (Note 3 and 4)		134,898		252,543
Total current liabilities		503,445		590,001
Long-term debt, excluding current portion (Note 10)		1,117,288		1,126,357
Long-term right-of-use obligations, excluding current portion (Note 16)		48,824		48,167
Insurance deposits and related liabilities (Note 12) Liability for pension and other postretirement plan benefits,		78,391		79,974
excluding current portion (Note 11)		228,606		224,752
Other liabilities		154,096		214,714
Total liabilities		2,130,650		2,283,965
Commitments and contingencies (Notes 3, 4, 6, 7, 10, 13, and 16)				
Net assets				
Net assets without donor restrictions (Note 9)		634,297		758,627
Net assets with donor restrictions (Notes 8 and 9)		199,503	_	184,270
Total net assets		833,800		942,897
Total liabilities and net assets	\$	2,964,450	\$	3,226,862

_

Dartmouth-Hitchcock Health and Subsidiaries Consolidated Statements of Operations and Changes in Net Assets Years Ended June 30, 2022 and 2021

(in thousands of dollars)	<u>2022</u>	<u>2021</u>
Operating revenue and other support Net patient service revenue (Note 4) Contracted revenue Other operating revenue (Note 4) Net assets released from restrictions	\$ 2,243,237 77,666 534,031 15,894	\$ 2,138,287 85,263 424,958 15,201
Total operating revenue and other support	2,870,828	2,663,709
Operating expenses Salaries Employee benefits Medications and medical supplies Purchased services and other Medicaid enhancement tax (Note 4) Depreciation and amortization Interest (Note 10) Total operating expenses	1,315,407 322,570 649,272 403,862 82,725 86,958 32,113 2,892,907	1,185,910 302,142 545,523 383,949 72,941 88,921 30,787 2,610,173
Operating (loss) income	(22,079)	53,536
Non-operating (losses) gains Investment (loss) income, net (Note 5) Other components of net periodic pension and post retirement benefit income (Note 11 and 14)	(78,744)	203,776
Other losses, net (Note 10)	(6,658)	(4,233)
Total non-operating (losses) gains, net	(71,492)	213,102
(Deficiency) excess of revenue over expenses	\$ (93,571)	\$ 266,638

Consolidated Statements of Operations and Changes in Net Assets – continues on next page

Dartmouth-Hitchcock Health and Subsidiaries Consolidated Statements of Operations and Changes in Net Assets - Continued Years Ended June 30, 2022 and 2021

(in thousands of dollars)		<u>2022</u>		<u>2021</u>
Net assets without donor restrictions (Deficiency) excess of revenue over expenses	\$	(93,571)	\$	266,638
Net assets released from restrictions for capital Change in funded status of pension and other postretirement	Ψ	1,573	Ψ	2,017
benefits (Note 11) Other changes in net assets		(32,309) (23)		59,132 (186)
(Decrease) increase in net assets without donor restrictions		(124,330)		327,601
Net assets with donor restrictions				
Gifts, bequests, sponsored activities		39,710		30,107
Investment (loss) income, net		(7,010)		19,153
Net assets released from restrictions		(17,467)		(17,218)
Increase in net assets with donor restrictions		15,233		32,042
Change in net assets		(109,097)		359,643
Net assets				
Beginning of year		942,897		583,254
End of year	\$	833,800	\$	942,897

Dartmouth-Hitchcock Health and Subsidiaries Consolidated Statements of Cash Flows Years Ended June 30, 2022 and 2021

(in thousands of dollars)	<u>2022</u>	<u>2021</u>
Cash flows from operating activities		
Change in net assets	\$ (109,097)	\$ 359,643
Adjustments to reconcile change in net assets to		
net cash provided by operating and non-operating activities	07.000	00.004
Depreciation and amortization	87,006	88,904
Amortization of bond premium, discount, and issuance cost, net	(2,764)	(2,820)
Amortization of right-of-use asset	9,270	10,034
Payments on right-of-use lease obligations - operating Change in funded status of pension and other postretirement benefits	(9,190) 32,309	(9,844) (59,132)
(Gain) loss on disposal of fixed assets	(523)	(39,132) 592
Net realized gains and change in net unrealized gains on investments	86,652	(228,489)
Restricted contributions and investment earnings	(20,151)	(3,445)
Proceeds from sales of donated securities	10,665	(0,++0)
Changes in assets and liabilities	10,000	
Patient accounts receivable, net	(19,089)	(48,342)
Prepaid expenses and other current assets	(9,915)	4,588
Other assets, net	2,517	(39,760)
Accounts payable and accrued expenses	17,104	1,223
Accrued compensation and related benefits	8,490	39,079
Estimated third-party settlements	(120,117)	9,787
Insurance deposits and related liabilities	(1,583)	2,828
Liability for pension and other postretirement benefits	(28,422)	(40,373)
Other liabilities	 (56,687)	 11,267
Net cash (used in) provided by operating activities	 (123,525)	 95,740
Cash flows from investing activities		
Purchase of property, plant, and equipment	(160,855)	(122,347)
Proceeds from sale of property, plant, and equipment	613	316
Purchases of investments	(65,286)	(95,943)
Proceeds from maturities and sales of investments	 137,781	 75,071
Net cash used in investing activities	 (87,747)	 (142,903)
Cash flows from financing activities		
Proceeds from line of credit	30,000	-
Payments on line of credit	(30,000)	-
Repayment of long-term debt	(9,116)	(9,183)
Repayment of finance leases	(3,253)	(3,117)
Payment of debt issuance costs	-	(230)
Restricted contributions and investment earnings	 20,151	 3,445
Net cash provided by (used in) financing activities	 7,782	 (9,085)
Decrease in cash and cash equivalents	(203,490)	(56,248)
Cash and cash equivalents, beginning of year	 396,975	 453,223
Cash and cash equivalents, end of year	\$ 193,485	\$ 396,975
Supplemental cash flow information		
Interest paid	\$ 42,867	\$ 41,819
Construction in progress included in accounts payable and		
accrued expenses	9,407	16,192
Donated securities	10,665	-

The following table reconciles cash and cash equivalents on the consolidated balance sheets to cash, cash equivalents and restricted cash on the consolidated statements of cash flows.

	2022	<u>2021</u>
Cash and cash equivalents	\$ 191,929	\$ 374,928
Cash and cash equivalents included in assets limited as to use	1,350	18,500
Restricted cash and cash equivalents included in other investments for restricted activities	 206	3,547
Total of cash, cash equivalents, and restricted cash shown		
in the consolidated statements of cash flows	\$ 193,485	\$ 396,975

1. Organization and Community Benefit Commitments

Dartmouth-Hitchcock Health (D-HH), its Members, and their Subsidiaries (the Health System) is a system of hospitals, clinics, and other healthcare service providers across New Hampshire and Vermont. The Health System's mission is to advance health through research, education, clinical practice, and community partnerships, providing each person the best care, in the right place, at the right time, every time. The Health System seeks to achieve the healthiest population possible, leading the transformation of health care in the region and setting the standard for the nation. The Health System's expanding network of services are the fabric of its commitment to serve the region with exceptional medical care.

Dartmouth-Hitchcock Health (D-HH) serves as the sole corporate member of the following entities: Dartmouth-Hitchcock Clinic (DHC) and Subsidiaries, Mary Hitchcock Memorial Hospital (MHMH) and Subsidiaries, (DHC and MHMH together are referred to as D-H), The New London Hospital Association, Inc. (NLH), Windsor Hospital Corporation (d/b/a Mt. Ascutney Hospital and Health Center) (MAHHC) and Subsidiaries, The Cheshire Medical Center (Cheshire) and Subsidiaries, Alice Peck Day Memorial Hospital (APD) and Subsidiaries.

The Health System currently operates one tertiary, one community, and three acute care (critical access) hospitals in New Hampshire (NH) and Vermont (VT). One facility provides inpatient and outpatient rehabilitation medicine and long-term care. The Health System also operates multiple physician practices, a continuing care retirement community, and a home health and hospice service. The Health System operates a graduate level program for health professions and is the principal teaching affiliate of the Geisel School of Medicine (Geisel), a component of Dartmouth College.

D-HH, DHC, MHMH, NLH, Cheshire, and APD are NH not-for-profit corporations exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code (IRC). MAHHC and VNH are VT not-for-profit corporations exempt from federal income taxes under Section 501(c)(3) of the IRC.

On September 30, 2019, D-HH and GraniteOne Health (GOH) entered into an agreement (The Combination Agreement) to combine their respective healthcare systems. The parties submitted filings with the Federal Trade Commission and the New Hampshire Attorney General's Office, seeking regulatory clearance of the proposed transaction. On May 13, 2022, D-HH and GOH ended their pursuit of regulatory approval of the transaction and terminated the Combination Agreement.

Community Benefits

Consistent with its mission, the Health System provides high quality, cost effective, comprehensive, and integrated healthcare to individuals, families, and the communities it serves regardless of a patient's ability to pay. The Health System actively supports community-based healthcare and promotes the coordination of services among healthcare providers and social services organizations. In addition, the Health System seeks to work collaboratively with other area healthcare providers to improve the health status of the region. As a component of an integrated

academic medical center, the Health System provides significant support for academic and research programs.

Certain member hospitals of the Health System file annual Community Benefits Reports with the State of NH, which outline the community and charitable benefits each provides. VT hospitals are not required by law to file a state Community Benefit Report. The categories used in the Community Benefit Reports to summarize these benefits are as follows:

- Community Health Improvement Services include activities carried out to improve community health, and could include community health education (such as classes, programs, support groups, and materials that promote wellness and prevent illness), community-based clinical services (such as free clinics and health screenings), and healthcare support services (enrollment assistance in public programs, assistance in obtaining free or reduced costs medications, telephone information services, or transportation programs to enhance access to care, etc.).
- *Health Professions Education* includes uncompensated costs of training medical students, residents, nurses, and other health care professionals
- Subsidized Health Services are services provided by the Health System, resulting in financial losses that meet the needs of the community and would not otherwise be available unless the responsibility was assumed by the government.
- *Research* includes costs, in excess of awards, for numerous health research and service initiatives within the Health System.
- Cash and In-Kind Contributions occur outside of the System through various financial contributions of cash, in-kind donations, and grants to local organizations.
- Community-Building Activities include expenses incurred to support the development of programs and partnerships intended to address public health challenges, as well as social and economic determinants of health. Examples include physical improvements and housing, economic development, support system enhancements, environmental improvements, leadership development and training for community members, community health improvement advocacy, and workforce enhancement.
- *Charity Care* includes losses, at-cost, incurred by providing health care services to persons qualifying for hospital financial assistance programs.
- The Uncompensated Cost of Care for Medicaid patients reported in the unaudited Community Benefits Reports for 2021 was approximately \$198,859,000. The 2022 Community Benefits Reports are expected to be filed in February 2023.

The following table summarizes the value of the community benefit initiatives outlined in the Health System's most recently filed Community Benefit Reports for the year ended June 30, 2021:

(in thousands of dollars)	
Uncompensated cost of care for Medicaid	\$ 198,859
Health professional education	41,554
Subsidized health services	16,785
Charity care	12,678
Community health improvement services	13,589
Research	4,839
Cash and In-Kind Contributions	4,741
Community building activities	 2,885
Total community benefit value	\$ 295,930

In fiscal years 2022 and 2021, funds received to offset or subsidize charity care costs provided were \$452,000 and \$848,000, respectively.

For fiscal year 2022, Medicare costs exceeding reimbursement totaled \$105,460,000.

2. Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America, and have been prepared consistent with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 954, *Healthcare Entities*, which addresses the accounting for healthcare entities. The net assets, revenue, expenses, gains, and losses of healthcare entities are classified based on the existence or absence of donor-imposed restrictions. Accordingly, net assets without donor restrictions are amounts not subject to donor-imposed stipulations and are available for operations. Net assets with donor restrictions are those whose use has been limited by donors to a specific time period or purpose, or whose use has been restricted by donors to be maintained in perpetuity. All significant intercompany transactions have been eliminated upon consolidation.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The most significant areas that are affected by the use of estimates include implicit and explicit pricing concessions, valuation of certain investments, estimated third-party settlements, insurance reserves, and pension obligations. Actual results may differ from those estimates.

(Deficiency) Excess of Revenue over Expenses

The Consolidated Statements of Operations and Changes in Net Assets include the (deficiency) excess of revenue over expenses. Operating revenues consist of those items attributable to the care of patients, including contributions and investment (loss) income on investments of net assets without donor restrictions, which are utilized to provide charity and other operational support. Peripheral activities, including realized gains/losses on sales of investment securities and changes in unrealized gains/losses on investments are reported as non-operating (losses) gains.

Changes in net assets without donor restrictions which are excluded from the (deficiency) excess of revenue over expenses, consistent with industry practice, include contributions of long-lived assets (including assets acquired using contributions which by donor restriction were to be used for the purpose of acquiring such assets), and change in funded status of pension and other postretirement benefit plans.

Charity Care

The Health System provides care to patients who meet certain criteria under their financial assistance policies without charge, or at amounts less than their established rates. Because the Health System does not anticipate collection of amounts qualifying as charity care, they are not reported as revenue.

The Health System grants credit, without collateral, to patients. Most are local residents and are insured under third-party arrangements. The amount of charges for implicit price concessions is based upon management's assessment of historical and expected net collections, business and economic conditions, trends in federal and state governmental healthcare coverage, and other collection indicators (Notes 1 and 4).

Patient Service Revenue

The Health System applies the accounting provisions of ASC 606, *Revenue from Contracts with Customers* (ASC 606). Patient service revenue is reported at the amount of consideration to which the Health System expects to be entitled from patients, third party payors, and others, for services rendered, including estimated retroactive adjustments under reimbursement agreements with third-party payors and implicit pricing concessions. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as estimates change or final settlements are determined (Note 4).

Contracted Revenue

The Health System has various Professional Service Agreements (PSAs), pursuant to which certain organizations purchase services of personnel employed by the Health System and also lease space and equipment. Revenue pursuant to these PSAs, and certain facility and equipment leases and other professional service contracts, have been classified as contracted revenue in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

Other Revenue

The Health System recognizes other revenue, which is not related to patient medical care but is central to the day-to-day operations of the Health System. Other revenue, which consists primarily of revenue from retail pharmacy, specialty pharmacy, and contract pharmacy, is recorded in the amounts to which it expects to be entitled in exchange for the prescriptions. Other revenue also includes Coronavirus Aid, Relief, and Economic Securities Act (CARES Act Provider Relief Funds)

from the Department of Health and Human Services (HHS), operating agreements, grant revenue, cafeteria sales, and other support service revenue (Note 3 and 4).

Cash Equivalents

Cash and cash equivalents include amounts on deposit with financial institutions, short-term investments with maturities of three months or less at the time of purchase, and other highly liquid investments (primarily cash management funds), which would be considered level 1 investments under the fair value hierarchy. All short-term, highly liquid, investments included within the Health System's endowment and similar investment pools, otherwise qualifying as cash equivalents, are classified as investments at fair value and, therefore, are excluded from cash and cash equivalents in the Consolidated Statements of Cash Flows.

Investments and Investment (Loss) Income

Investments in equity securities with readily determinable fair values, mutual funds, governmental securities, debt securities, and pooled/commingled funds are reported at fair value with changes in fair value included in the (deficiency) excess of revenues over expenses. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (Note 7).

Investments in pooled/commingled investment funds, private equity funds, and hedge funds that represent investments where the Health System owns shares or units of funds rather than the underlying securities in that fund are valued using the equity method of accounting with changes in value recorded in the (deficiency) excess of revenue over expenses.

Certain members of the Health System are partners in a NH general partnership established for the purpose of operating a master investment program of pooled investment accounts. Substantially all of the Health System's board-designated and assets with donor restrictions, such as endowment funds, were invested in these pooled funds by purchasing units based on the market value of the pooled funds at the end of the month prior to receipt of any new additions to the funds. Interest, dividends, and realized and unrealized gains and losses earned on pooled funds are allocated monthly based on the weighted average units outstanding at the prior month-end.

Investment income or losses (including change in unrealized and realized gains and losses on investments, change in value of equity method investments, interest, and dividends) are included in the (deficiency) excess of revenue over expenses and classified as non-operating gains and losses, unless the income or loss is restricted by donor or law (Note 9).

Fair Value Measurement of Financial Instruments

The Health System estimates fair value based on a valuation framework that uses a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of fair value hierarchy, as defined by ASC 820, *Fair Value Measurements and Disclosures*, are described below:

Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for assets or liabilities.

- Level 2 Prices other than quoted prices in active markets that are either directly or indirectly observable as of the date of measurement.
- Level 3 Prices or valuation techniques that are both significant to the fair value measurement and unobservable.

The carrying amounts of patient accounts receivable, prepaid and other current assets, accounts payable and accrued expenses approximate fair value due to the short maturity of these instruments.

Property, plant, and equipment

Property, plant, and equipment, and other real estate are stated at cost at the time of purchase or fair value at the time of donation, less accumulated depreciation. The Health System's policy is to capitalize expenditures for major improvements and to charge expense for maintenance and repair expenditures which do not extend the lives of the related assets. The provision for depreciation has been determined using the straight-line method at rates which are intended to amortize the cost of assets over their estimated useful lives which range from 10 to 40 years for buildings and improvements, 2 to 20 years for equipment, and the shorter of the lease term, or 5 to 12 years, for leasehold improvements. Certain software development costs are amortized using the straight-line method over a period of up to 10 years. Net interest cost incurred on borrowed funds during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets.

The fair value of a liability for legal obligations associated with asset retirements is recognized in the period in which it is incurred, if a reasonable estimate of the fair value of the obligation can be made. When a liability is initially recorded, the cost of the asset retirement obligation is capitalized by increasing the carrying amount of the related long-lived asset. Over time, the liability is accreted to its present value each period and the capitalized cost associated with the retirement is depreciated over the useful life of the related asset. Upon settlement of the obligation, any difference between the actual cost to settle the asset retirement obligation and the liability recorded is recognized as a gain or loss in the consolidated statements of operations and changes in net assets.

Gifts of capital assets such as land, buildings, or equipment are reported as support, and excluded from the (deficiency) excess of revenue over expenses, unless explicit donor stipulations specify how the donated assets must be used. Gifts of capital assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire capital assets are reported as restricted support. Absent explicit donor stipulations about how long those capital assets must be maintained, expirations of donor restrictions are reported when the donated or acquired capital assets are placed in service.

Bond Issuance Costs

Bond issuance costs, classified on the consolidated balance sheets within long-term debt, are amortized over the term of the related bonds. Amortization is recorded within interest expense in the consolidated statements of operations and changes in net assets using the straight-line method which approximates the effective interest method.

Intangible Assets and Goodwill

The Health System records within other assets on the consolidated balance sheets goodwill and intangible assets such as trade names and leases-in-place. The Health System considers trade names and goodwill to be indefinite-lived assets, assesses them at least annually for impairment or more frequently if certain events or circumstances warrant and recognizes impairment charges for amounts by which the carrying values exceed their fair values. The Health System has recorded \$8,885,000 and \$9,403,000 as intangible assets as of June 30, 2022 and 2021, respectively.

Gifts

Gifts without donor restrictions are recorded net of related expenses as non-operating gains. Conditional promises to give and indications of intentions to give to the Health System are reported at fair value at the date the gift is received. Gifts are reported with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified as net assets without donor restrictions and reported in the consolidated statements of operations and changes in net assets as net assets released from restrictions.

Recently Issued Accounting Pronouncements

In March 2020, January 2021, and April 2022, the FASB issued standard updates on Reference Rate Reform in response to the planned discontinuation of the London Inter-Bank Offered Rate (LIBOR), a key interbank reference rate. The standard provides accounting relief to contract modifications and optional expedients for applying U.S. GAAP to contracts and other transactions that reference LIBOR or other reference rates that are expected to be discontinued because of rate reform. The Health System is currently in the process of evaluating the impact of adoption of these standards on the financial statements.

3. The COVID-19 Pandemic

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic resulting in an extraordinary disruption to our nation's healthcare system. In response to COVID-19, the Coronavirus Aid Relief and Economic Security (CARES) Act was enacted which provided different types of economic support to a wide variety of organizations and individuals. The Health System employed several CARES Act provisions, with the most significant impacts summarized below.

Health and Human Services Provider Relief Funds

The Health System received \$100,346,000 and \$65,600,000 in CARES Act Provider Relief Funds for the years ended June 30, 2022 and 2021, respectively. The Health System will continue to pursue Provider Relief Funds as available, and as needed, to support the Health System.

In July 2020, HHS issued reporting requirements for CARES Act Provider Relief Funds, requiring recipients to identify healthcare-related expenses that remain unreimbursed by another source, attributable to the COVID-19 pandemic. If those expenses do not exceed the funding received, recipients will need to demonstrate that the remaining funds were used to compensate for a negative variance in patient service revenue. HHS is entitled to recoup Provider Relief Funds

awarded in excess of expenses attributable to the COVID-19 pandemic that were not reimbursed by another source plus losses incurred due to the decline in patient care revenue. There have been no recoupments through June 2022.

Medicare and Medicaid Services (CMS) Accelerated and Advance Payment Program

The Health System received CMS prepayment advances, related to the CARES Act, totaling \$245,200,000. In addition, the Health System accumulated payroll tax deferrals of \$33,100,000. Repayment of funds commenced in April 2021. The balances of CMS prepayment advances and accumulated payroll tax deferrals at June 30, 2022 were \$54,890,000 and \$16,550,000, respectively, and are included in estimated third party settlements and accrued compensation and related benefits on the Consolidated Balance Sheets.

The Health System continues to address the challenges and impacts of the COVID-19 pandemic including protecting the health and safety of employees and patients as well as assessing the availability of personal protective equipment and other needed supplies to be better positioned for potential surges. Additionally, the Health System continues to evaluate the impact of new or changes to laws and regulations at the federal, state, and local levels and the potential effect on Health System staffing and operations. At this time, the Health System cannot accurately predict the full extent to which the COVID-19 pandemic will affect the Health System's future finances and operations.

4. Net Patient Service Revenue and Accounts Receivable

The Health System reports net patient service revenue at amounts that reflect the consideration to which it expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payers (including managed care payers and government programs), and others; and they include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Health System bills patients and third-party payers several days after the services were performed or shortly after discharge. Revenue is recognized as performance obligations are satisfied under contracts by providing healthcare services to patients.

The Health System determines performance obligations based on the nature of the services provided. Revenues for performance obligations satisfied over time are recognized based on actual charges incurred in relation to total expected charges as this method provides a reasonable estimate of the transfer of services over the term of performance obligations based on inputs needed to satisfy the obligations. Generally, performance obligations satisfied over time relate to patients receiving inpatient acute care services. For inpatient services, performance obligations are measured from admission to the point when there are no further services required for the patient, which is generally the time of discharge. For outpatient services and physician services, performance obligations are recognized at a point in time when the services are provided and no further patient services are deemed necessary.

Generally, the Health System's patient service performance obligations relate to contracts with a duration of less than one year, therefore the Health System has elected to apply the optional exemption provided in ASC 606-10-50-14a and, therefore, we are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied

or partially unsatisfied at the end of the reporting period. This generally refers to inpatient services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

Established charges represent gross charges. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately entitled to for services it provides. Therefore, they are not displayed in the Health System's consolidated statements of operations and changes in net assets.

Hospitals are paid amounts negotiated with insurance companies or set by government entities, which are typically less than established or standard charges. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts. Gross charges are what hospitals charge all patients prior to the application of contractual adjustments and implicit price concessions.

Explicit Pricing Concessions

Revenues for the Health System under the traditional fee-for service Medicare and Medicaid programs are based on prospectively determined rates per discharge or visit, reasonable (allowable) cost, or prospective rates per episodic period, depending on the type of provider.

- Inpatient acute care services provided to Medicare program beneficiaries are paid using the prospective payment system (PPS) to determine rates-per-discharge. These rates vary according to a patient classification system (DRG), based on diagnostic, clinical, and other factors. In addition, inpatient capital costs (depreciation and interest) are reimbursed by Medicare on the basis of a prospectively determined rate per discharge. Medicare outpatient services are paid on a prospective payment system, based on a pre-determined amount for each outpatient procedure (APC), subject to various mandated modifications. Retrospectively determined cost-based revenues under these programs, such as indirect medical education, direct graduate medical education, disproportionate share hospital, transplant services, and bad debt reimbursement are based on the hospital's cost reports and are estimated using historical trends and current factors. The Health System's payments for inpatient services rendered to NH and VT Medicaid beneficiaries are based on PPS, while outpatient services are reimbursed on a retrospective cost basis, or fee schedules, for NH beneficiaries. VT outpatient beneficiaries are paid on a prospective basis per outpatient procedure.
- Inpatient acute, swing, and outpatient services furnished by Critical Access Hospitals (CAH) are reimbursed by Medicare at 101% of reasonable costs, subject to 2% sequestration, excluding ambulance services and inpatient hospice care.
- Providers of home health services to patients eligible for Medicare home health benefits are paid on a prospective basis, with no retrospective settlement. The prospective payment is based on the scoring attributed to the acuity level of the patient at a rate determined by federal guidelines.

- Hospice services to patients eligible for Medicare hospice benefits are paid on a per diem basis, with no retrospective settlement, provided the aggregate annual Medicare reimbursement is below a predetermined aggregate capitated rate.
- The Health System's cost based services to Medicare and Medicaid are reimbursed during the year based on varying interim payment methodologies. Final settlement is determined after the submission of an annual cost report and subject to audit of this report by Medicare and Medicaid auditors, as well as administrative and judicial review. Because the laws, regulations, and rule interpretations, governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates recorded could change over time by material amounts.
- Revenues under Managed Care Plans (MCPs) consist primarily of payment terms involving mutually agreed upon rates per diagnosis, discounted fee-for service rates, or similar contractual arrangements. These revenues are also subject to review and possible audit. The MCPs are billed for patient services on an individual patient basis. An individual patient's bill is subject to adjustments in accordance with contractual terms in place with the MCPs following their review and adjudication of each bill.

The Health System is not aware of any claims, disputes, or unsettled matters with any payer that would materially affect its revenues for which it has not adequately provided in the accompanying Health System's consolidated financial statements.

The Health System provides charity care to patients who are unable to pay for healthcare services they receive as determined by financial conditions. Patients who qualify receive partial or full adjustments to charges for services rendered. The Health System's policy is to treat amounts qualified as charity care as explicit price concessions and, as such, are not reported in net patient service revenue.

Vermont imposes a provider tax on home health agencies in the amount of 4.25% of Vermont annual net patient revenue. In fiscal years 2022 and 2021, home health provider taxes paid were \$627,000 and \$623,000, respectively.

Implicit Price Concessions

Generally, patients who are covered by third-party payer contracts are responsible for related copays, co-insurance, and deductibles, which vary depending on the contractual obligations of patients. The Health System also provides services to uninsured patients and offers those patients a discount from standard charges. The Health System estimates the transaction price for patients with co-pays, co-insurance, and deductibles, and for those who are uninsured based on historical collection experience and current market conditions. The discount offered to uninsured patients reduces the transaction price at the time of billing. The uninsured and patient responsible accounts, net of discounts recorded, are further reduced through implicit price concessions based on historical collection trends for similar accounts and other known factors that impact the estimation process. Subsequent changes to the estimate of transaction price are generally recorded as adjustments to net patient services revenue in the period of change.

The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts the Health System expects to collect based on

collection history with similar patients. Although outcomes vary, the Health System's policy is to attempt to collect amounts due from patients, including co-pays, co-insurance, and deductibles due from insurance at the time of service while complying with all federal and state statutes and regulations, including but not limited to, the Emergency Medical Treatment and Active Labor Act (EMTALA). Through various systems and processes the Health System estimates Medicare and Medicaid net patient service revenue and cost report settlements and accrues final expected settlements. For filed cost reports, the accrual is recorded based on those filings, subsequent activity, and on historical trends and other relevant evidence. For periods in which a cost report is yet to be filed, accruals are based on estimates of what is expected to be reported, and any trends and relevant evidence. Cost reports generally must be filed within five months of the closing period.

Settlements with third-party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care using the most likely amount. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer, and historical settlement activity, including assessments to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews or investigations. As of June 30, 2022 and 2021, the Health System had reserves of \$134,898,000 and \$252,543,000, respectively, recorded in estimated third-party settlements. As of June 30, 2022 and 2021, estimated third-party settlements. As of June 30, 2022 and 2021, estimated third-party settlements. As of June 30, 2022 and 2021, estimated third-party settlements, reviews or investigations. ("COVID-19") outbreak.

For the years ended June 30, 2022 and 2021, additional increases in revenue of \$19,743,000 and \$4,287,000, respectively, were recognized due to changes in estimates of implicit price concessions for performance obligations satisfied in prior years.

Net operating revenues consist primarily of patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans as well as patients covered under the Health System's uninsured discount and charity care programs.

The table below shows the Health System's sources of total operating revenue and other support presented at the net transaction price for the years ended June 30, 2022 and 2021.

		2022	
(in thousands of dollars)	 PPS	<u>CAH</u>	<u>Total</u>
Hospital			
Medicare	\$ 542,292	\$ 99,976	\$ 642,268
Medicaid	158,121	15,739	173,860
Commercial	809,736	81,395	891,131
Self-pay	 7,027	 902	 7,929
Subtotal	1,517,176	198,012	1,715,188
Professional	 470,559	 40,186	 510,745
Subtotal	1,987,735	238,198	2,225,933
Home based care			17,304
Subtotal			 2,243,237
Other revenue			528,762
Provider Relief Funds			 98,829
Total operating revenue and other support			\$ 2,870,828

		2021	
(in thousands of dollars)	PPS	CAH	Total
Hospital			
Medicare	\$ 526,114	\$ 81,979	\$ 608,093
Medicaid	144,434	11,278	155,712
Commercial	793,274	73,388	866,662
Self-pay	 4,419	(721)	 3,698
Subtotal	1,468,241	165,924	1,634,165
Professional	 446,181	 37,935	 484,116
Subtotal	1,914,422	203,859	2,118,281
Home based care			 20,006
Subtotal			 2,138,287
Other revenue			462,517
Provider Relief Funds			 62,905
Total operating revenue and other support			\$ 2,663,709

Medicaid Enhancement Tax & Disproportionate Share Hospital

On May 22, 2018, the State of New Hampshire and all New Hampshire hospitals (Hospitals) agreed to resolve disputed issues and enter into a seven-year agreement to stabilize Disproportionate Share Hospital (DSH) payments, with provisions for alternative payments in the

event of legislative changes to the DSH program. Under the agreement, the State committed to make DSH payments to the Hospitals in an amount no less than 86% of the Medicaid Enhancement Tax (MET) proceeds collected in each fiscal year, in addition to providing for directed payments or increased rates for Hospitals in an amount equal to 5% of MET proceeds collected from state fiscal year (SFY) 2021 through SFY 2024. The agreement prioritizes DSH payments to critical access hospitals in an amount equal to 75% of allowable uncompensated care (UCC), with the remainder distributed to Hospitals without critical access designation in proportion to their allowable UCC amounts.

During the years ended June 30, 2022 and 2021, the Health System received DSH payments of approximately, \$77,488,000 and \$67,940,000, respectively. DSH payments are subject to audit and, therefore, for the years ended June 30, 2022 and 2021, the Health System recognized as revenue DSH receipts of approximately \$75,988,000 and approximately \$61,602,000, respectively.

During the years ended June 30, 2022 and 2021, the Health System recorded \$82,725,000 and \$72,941,000, respectively, of State of NH MET and State of VT provider taxes. The taxes are calculated at 5.4% for NH and 6% for VT of certain patient service revenues. The Provider taxes are included in operating expenses in the Consolidated Statements of Operations and Changes in Net Assets.

Accounts Receivable

The following table categorizes payors into four groups based on their respective percentages of patient accounts receivable as of June 30, 2022 and 2021:

	<u>2022</u>	<u>2021</u>
Medicare	38%	34%
Medicaid	12%	13%
Commercial	38%	41%
Self Pay	12%	12%
Total	100%	100%

5. Investments

The composition of investments at June 30, 2022 and 2021 is set forth in the following table:

(in thousands of dollars)	<u>2022</u>		<u>2021</u>
Assets limited as to use			
Internally designated by board			
Cash and short-term investments	\$ 31,130	\$	24,692
U.S. government securities	126,222		157,373
Domestic corporate debt securities	234,490		322,616
Global debt securities	68,610		74,292
Domestic equities	198,742		247,486
International equities	63,634		81,060
Emerging markets equities	34,636		52,636
Global equities Real Estate Investment Trust	73,035 2		79,296 422
	∠ 138,605		422 110,968
Private equity funds Hedge funds	55,069		-
Subtotal	 1,024,175		1,150,841
	1,024,175		1,130,041
Investments held by captive insurance companies (Note 12)	07 040		26 750
U.S. government securities Domestic corporate debt securities	27,242 7,902		26,759 5,979
Global debt securities	7,902		5,979 6,617
Domestic equities	10,091		11,396
International equities	4,692		6,488
Subtotal	 57,522		57,239
Held by trustee under indenture agreement (Note 9)	- ,-		- ,
Cash and short-term investments	99,397		170,399
Total assets limited as to use	1,181,094	_	1,378,479
Other investments for restricted activities			
Cash and short-term investments	8,463		13,400
U.S. government securities	27,600		28,330
Domestic corporate debt securities	37,343		40,676
Global debt securities	10,059		8,953
Domestic equities	34,142		33,634
International equities	10,698		9,497
Emerging markets equities	5,587		5,917
Global equities	11,153		8,755
Real Estate Investment Trust	19		21
Private equity funds	21,166		12,251
Hedge funds	8,852		6,557
Other	 34		44
Total other investments for restricted activities	 175,116		168,035
Total investments	\$ 1,356,210	\$	1,546,514

Investments are accounted for using either the fair value method or equity method of accounting, as appropriate on a case by case basis. The fair value method is used for all debt securities and equity securities that are traded on active markets and are valued at prices that are readily available in those markets. The equity method is used when investments are made in pooled/commingled investment funds that represent investments where shares or units are owned of pooled funds rather than the underlying securities in that fund. These pooled/commingled funds make underlying investments in securities from the asset classes listed above.

The following tables summarize the investments by the accounting method utilized as of June 30, 2022 and 2021. Accounting standards require disclosure of additional information for those securities accounted for using the fair value method, as shown in Note 7.

			2022	
(in thousands of dollars)	<u>F</u> a	air Value	<u>Equity</u>	Total
Cash and short-term investments	\$	138,990	\$ -	\$ 138,990
U.S. government securities		181,064	-	181,064
Domestic corporate debt securities		118,642	161,093	279,735
Global debt securities		57,558	28,706	86,264
Domestic equities		191,767	51,208	242,975
International equities		47,631	31,393	79,024
Emerging markets equities		298	39,926	40,224
Global equities		-	84,187	84,187
Real Estate Investment Trust		21	-	21
Private equity funds		-	159,771	159,771
Hedge funds		443	63,478	63,921
Other		34	 -	 34
Total investments	\$	736,448	\$ 619,762	\$ 1,356,210

	2021							
(in thousands of dollars)	Fair Value			<u>Equity</u>	<u>Total</u>			
Cash and short-term investments	\$	208,491	\$	-	\$	208,491		
U.S. government securities		212,462		-		212,462		
Domestic corporate debt securities		191,112		178,159		369,271		
Global debt securities		55,472		34,390		89,862		
Domestic equities		225,523		66,993		292,516		
International equities		55,389		41,656		97,045		
Emerging markets equities		1,888		56,665		58,553		
Global equities		-		88,051		88,051		
Real Estate Investment Trust		443		-		443		
Private equity funds		-		123,219		123,219		
Hedge funds		446		6,111		6,557		
Other		44		-		44		
Total investments	\$	951,270	\$	595,244	\$	1,546,514		

For the years ended June 30, 2022 and 2021, investment (loss) income is reflected in the accompanying Consolidated Statements of Operations and Changes in Net Assets as other operating revenue of approximately \$857,000 and \$930,000, respectively, and as non-operating (losses) gains of approximately (\$78,744,000) and \$203,776,000, respectively.

Private equity limited partnership shares are not eligible for redemption from the fund or general partner. It is the intent of the Health System to hold these investments until the fund has fully distributed all proceeds to the limited partners and the term of the partnership agreements expire. Under the terms of these agreements, the Health System has committed to contribute a specified level of capital over a defined period of time. Through June 30, 2022 and 2021, the Health System has outstanding commitments of \$75,070,000 and \$47,419,000, respectively.

6. **Property, Plant, and Equipment**

Property, plant, and equipment consists of the following at June 30, 2022 and 2021:

(in thousands of dollars)	<u>2022</u>	<u>2021</u>
Land	\$ 40,749	\$ 40,749
Construction in progress Land improvements	163,145 44,834	80,231 43,927
Buildings and improvements Equipment	984,743 1,042,582	955,094 993,899
Subtotal property, plant, and equipment	 2,276,053	 2,113,900
Less accumulated depreciation	 1,511,213	 1,433,467
Total property, plant, and equipment, net	\$ 764,840	\$ 680,433

As of June 30, 2022, construction in progress primarily consists of three projects; an in-patient tower, an emergency department (ED) expansion, and a central pharmacy/supply chain facility renovation. The estimated cost to complete the in-patient tower is \$52,400,000 with an anticipated completion date occurring in the fourth quarter of fiscal 2023. The estimated cost to complete the ED expansion is \$2,000,000 with an expected completion date occurring in the first quarter of fiscal 2023. The estimated cost to complete the central pharmacy/supply chain facility is \$1,600,000 with an expected completion date occurring in the first quarter of fiscal 2023.

The construction in progress as of June 30, 2021, included the Manchester Ambulatory Surgical Center (ASC) and the in-patient tower in Lebanon, NH. The ASC was fully operational in October 2021.

Capitalized interest of \$6,853,000 and \$5,127,000 is included in construction in progress as of June 30, 2022 and 2021, respectively.

Depreciation expense included in operating and non-operating activities was \$83,661,000 and \$86,011,000 for 2022 and 2021, respectively.

7. Fair Value Measurements

The following is a description of the valuation methodologies for assets and liabilities measured at fair value on a recurring basis:

Cash and Short-Term Investments

Consists of money market funds and are valued at net asset value (NAV) reported by the financial institution and cash which will be used for future investment opportunities.

Domestic, Emerging Markets and International Equities

Consists of actively traded equity securities and mutual funds which are valued at the closing price reported on an active market on which the individual securities are traded (Level 1 measurements).

U.S. Government Securities, Domestic Corporate and Global Debt Securities

Consists of U.S. government securities, domestic corporate and global debt securities, mutual funds and pooled/commingled funds that invest in U.S. government securities, domestic corporate and global debt securities. Securities are valued based on quoted market prices or dealer quotes where available (Level 1 measurement). If quoted market prices are not available, fair values are based on quoted market prices of comparable instruments or, if necessary, matrix pricing from a third party pricing vendor to determine fair value (Level 2 measurements). Matrix prices are based on quoted prices for securities with similar coupons, ratings and maturities, rather than on specific bids and offers for a designated security. Investments in mutual funds are measured based on the quoted NAV as of the close of business in the respective active market (Level 1 measurements).

Investments are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The following tables set forth the consolidated financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2022 and 2021:

	2022							
(in thousands of dollars)		Level 1		Level 2		Level 3		Total
Assets								
Investments								
Cash and short term investments	\$	138,990	\$	-	\$	-	\$	138,990
U.S. government securities		181,064		-		-		181,064
Domestic corporate debt securities		1,768		116,874		-		118,642
Global debt securities		24,745		32,813		-		57,558
Domestic equities		187,063		4,704		-		191,767
International equities		47,631		-		-		47,631
Emerging market equities		298		-		-		298
Real estate investment trust		21		-		-		21
Hedge funds		443		-		-		443
Other		-		34		-		34
Total fair value investments		582,023		154,425		-		736,448
Deferred compensation plan assets								
Cash and short-term investments		8,053		-		-		8,053
U.S. government securities		36		-		-		36
Domestic corporate debt securities		10,874		-		-		10,874
Global debt securities		964		-		-		964
Domestic equities		33,742		-		-		33,742
International equities		4,911		-		-		4,911
Emerging market equities		19		-		-		19
Real estate		12		-		-		12
Multi strategy fund		57,964		-		-		57,964
Total deferred compensation								
plan assets		116,575		-		-		116,575
Beneficial interest in trusts		-		-	_	16,051		16,051
Total assets	\$	698,598	\$	154,425	\$	16,051	\$	869,074

	2021						
(in thousands of dollars)		Level 1		Level 2		Level 3	<u>Total</u>
Assets							
Investments							
Cash and short term investments	\$	208,491	\$	-	\$	-	\$ 208,491
U.S. government securities		212,462		-		-	212,462
Domestic corporate debt securities		36,163		154,949		-	191,112
Global debt securities		27,410		28,062		-	55,472
Domestic equities		220,434		5,089		-	225,523
International equities		55,389		-		-	55,389
Emerging market equities		1,888		-		-	1,888
Real estate investment trust		443		-		-	443
Hedge funds		446		-		-	446
Other		9		35		-	 44
Total fair value investments		763,135		188,135		-	 951,270
Deferred compensation plan assets							
Cash and short-term investments		6,099		-		-	6,099
U.S. government securities		48		-		-	48
Domestic corporate debt securities		10,589		-		-	10,589
Global debt securities		1,234		-		-	1,234
Domestic equities		37,362		-		-	37,362
International equities		5,592		-		-	5,592
Emerging market equities		39		-		-	39
Real estate		15		-		-	15
Multi strategy fund		65,257		-		-	65,257
Guaranteed contract		-		-		-	 -
Total deferred compensation							
plan assets		126,235		-		-	 126,235
Beneficial interest in trusts		-		-		10,796	 10,796
Total assets	\$	889,370	\$	188,135	\$	10,796	\$ 1,088,301

The following tables set forth the financial instruments classified by the Health System within Level 3 of the fair value hierarchy defined above as of June 30, 2022 and 2021.

		2022	
(in thousands of dollars)	Beneficial Interest in Perpetual <u>Trust</u>		
Beginning of year balance Net realized/unrealized gains	\$	10,796 5,255	
End of year balance	\$	16,051	

	2021								
(in thousands of dollars)	In	eneficial terest in erpetual <u>Trust</u>		ranteed <u>ntract</u>		Total			
Beginning of year balance Net realized/unrealized gains (losses)	\$	9,202 1,594	\$	92 (92)	\$	9,294 1,502			
End of year balance	\$	10,796	\$	-	\$	10,796			

There were no transfers into and out of Level 1 and 2 measurements due to changes in valuation methodologies during the years ended June 30, 2022 and 2021.

8. Net Assets with Donor Restrictions

Net assets with donor restrictions are available for the following purposes at June 30, 2022 and 2021:

(in thousands of dollars)	<u>2022</u>	<u>2021</u>
Investments held in perpetuity	\$ 84,117	\$ 64,498
Healthcare services	36,123	38,869
Health education	27,164	26,934
Research	27,477	24,464
Charity care	12,155	15,377
Other	8,639	7,215
Purchase of equipment	 3,828	 6,913
Total net assets with donor restrictions	\$ 199,503	\$ 184,270

Income earned on donor restricted net assets held in perpetuity is available for these purposes.

9. Board Designated and Endowment Funds

Net assets include funds established for a variety of purposes including both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments. Net assets associated with endowment funds, including funds designated by the Board of Trustees to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

The Health System has interpreted the NH and VT Uniform Prudent Management of Institutional Funds Acts (UPMIFA or Act) for donor-restricted endowment funds as requiring the preservation of the original value of gifts, as of the gift date, to donor-restricted endowment funds, absent explicit donor stipulations to the contrary. The Health System's net assets with donor restrictions, which are to be held in perpetuity, consist of (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to be held in perpetuity, and (c)

accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund, if any. Collectively these amounts are referred to as the historic dollar value of the fund.

Net assets without donor restrictions include funds designated by the Board of Trustees to function as endowments, the income from certain donor-restricted endowment funds, and any accumulated investment return thereon, which pursuant to donor intent may be expended based on trustee or management designation. Net assets with donor restrictions that are temporary in nature, either restricted by time or purpose, include funds appropriated for expenditure pursuant to endowment and investment spending policies, certain expendable endowment gifts from donors, and any retained income and appreciation on donor-restricted endowment funds, which are restricted by the donor to a specific purpose or by law. When the restrictions on these funds have been met, the funds are reclassified to net assets without donor restrictions.

In accordance with the Act, the Health System considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds: the duration and preservation of the fund; the purposes of the donor-restricted endowment fund; general economic conditions; the possible effect of inflation and deflation; the expected total return from income and the appreciation of investments; other resources available; and investment policies.

The Health System has endowment investment and spending policies that attempt to provide a predictable stream of funding for programs supported by its endowment while ensuring that the purchasing power does not decline over time. The Health System targets a diversified asset allocation that places emphasis on investments in domestic and international equities, fixed income, private equity, and hedge fund strategies to achieve its long-term return objectives within prudent risk constraints. The Health System's Investment Committee reviews the policy portfolio asset allocations, exposures, and risk profile on an ongoing basis.

The Health System, as a policy, may appropriate for expenditure or accumulate so much of an endowment fund as the institution determines is prudent for the uses, benefits, purposes, and duration for which the endowment is established, subject to donor intent expressed in the gift instrument and the standard of prudence prescribed by the Act.

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below their original contributed value. Such market losses were not material as of June 30, 2022 and 2021.

Endowment net asset composition by type of fund consists of the following at June 30, 2022 and 2021:

				2022	
(in thousands of dollars)		Vithout Donor strictions	Re	With Donor estrictions	<u>Total</u>
Donor-restricted endowment funds Board-designated endowment funds	\$	- 41,344	\$	107,590 -	\$ 107,590 41,344
Total endowed net assets	\$	41,344	\$	107,590	\$ 148,934
				2021	
(in thousands of dollars)	-	Vithout Donor strictions	Re	With Donor estrictions	<u>Total</u>
Donor-restricted endowment funds Board-designated endowment funds	\$	- 41,728	\$	108,213 -	\$ 108,213 41,728
Total endowed net assets	\$	41,728	\$	108,213	\$ 149,941

Changes in endowment net assets for the years ended June 30, 2022 and 2021 are as follows:

	2022								
(in thousands of dollars)		Without Donor Restrictions		With Donor estrictions		<u>Total</u>			
Beginning of year balances Net investment return Contributions Transfers Release of appropriated funds	\$	41,728 (1,065) - 795 (114)	\$	108,213 (3,998) 12,950 (7,105) (2,470)	\$	149,941 (5,063) 12,950 (6,310) (2,584)			
End of year balances	\$	41,344	\$	107,590	\$	148,934			
End of year balances				107,590					
Beneficial interest in perpetual trusts				14,903					
Net assets with donor restrictions			\$	122,493					

	2021								
(in thousands of dollars)	-	Vithout Donor strictions	Re	With Donor strictions		<u>Total</u>			
Beginning of year balances Net investment return Contributions Transfers Release of appropriated funds	\$	33,714 7,192 894 - (72)	\$	80,039 17,288 13,279 418 (2,811)	\$	113,753 24,480 14,173 418 (2,883)			
End of year balances	\$	41,728	\$	108,213	\$	149,941			
End of year balances Beneficial interest in perpetual trusts				108,213 9,721					
Net assets with donor restrictions			\$	117,934					

10. Long-Term Debt

A summary of obligated group debt at June 30, 2022 and 2021 is as follows:

(in thousands of dollars)	<u>2022</u>	<u>2021</u>
Variable rate issues New Hampshire Health and Education Facilities Authority (NHHEFA) Revenue Bonds Series 2018A, principal maturing in varying annual amounts, through August 2037 (1)	\$ 83,355	\$ 83,355
Fixed rate issues New Hampshire Health and Education Facilities Authority Revenue Bonds Series 2018B, principal maturing in varying annual		
amounts, through August 2048 (1) Series 2020A, principal maturing in varying annual	303,102	303,102
amounts, through August 2059 (2) Series 2017A, principal maturing in varying annual	125,000	125,000
amounts, through August 2040 (3) Series 2017B, principal maturing in varying annual	122,435	122,435
amounts, through August 2031 (3) Series 2019A, principal maturing in varying annual	109,800	109,800
amounts, through August 2043 (4) Series 2018C, principal maturing in varying annual	99,165	99,165
amounts, through August 2030 (5) Series 2012, principal maturing in varying annual	23,950	24,425
amounts, through July 2039 (6) Series 2014B, principal maturing in varying annual	22,605	23,470
amounts, through August 2033 (7) Series 2016B, principal maturing in varying annual	14,530	14,530
amounts, through August 2045 (8) Series 2014A, principal maturing in varying annual	10,970	10,970
amounts, through August 2022 (7) Note payable	4,810	12,385
Note payable to a financial institution due in monthly interest only payments through May 2035 (9)	125,000	125,000
Total obligated group debt	\$ 1,044,722	\$ 1,053,637

A summary of long-term debt at June 30, 2022 and 2021 is as follows:

(in thousands of dollars)	<u>2022</u>			<u>2021</u>
Other				
Mortgage note payable to the US Dept of Agriculture;				
monthly payments of \$10,892 include interest of 2.375% through November 2046	\$	2,417	\$	2,489
Note payable to a financial institution with entire	Ψ	2,417	Ψ	2,400
principal due June 2034; collateralized by land				
and building. The note payable is interest free		247		273
Note payable to a financial institution payable in interest free monthly installments through December 2024;				
collateralized by associated equipment		55		147
Total nonobligated group debt		2,719		2,909
Total obligated group debt		1,044,722		1,053,637
Total long-term debt		1,047,441		1,056,546
Add: Original issue premium and discounts, net		83,249		86,399
Less: Current portion		6,596		9,407
Debt issuance costs, net		6,806		7,181
Total long-term debt, net	\$	1,117,288	\$	1,126,357

Aggregate annual principal payments for the next five years ending June 30 and thereafter are as follows:

(in thousands of dollars)	<u>2022</u>		
2023	\$ 6,596		
2024	15,207		
2025	19,362		
2026	20,209		
2027	20,915		
Thereafter	 965,152		
Total	\$ 1,047,441		

Dartmouth-Hitchcock Obligated Group (DHOG) Debt

MHMH established the DHOG for the purpose of issuing bonds financed through NHHEFA or the "Authority". The members of the obligated group consist of D-HH, MHMH, DHC, Cheshire, NLH, MAHHC, and, APD. D-HH is designated as the obligated group agent.

Revenue bonds, issued by members of the DHOG, are administered through notes registered in the name of the Bond Trustee and in accordance with the terms of a Master Trust Indenture. The Master Trust Indenture contains provisions permitting the addition, withdrawal, or consolidation of members of the DHOG under certain conditions. The notes constitute a joint and several obligation

of the members of the DHOG (and any other future members of the DHOG) and are equally and ratably collateralized by a pledge of the members' gross receipts. The DHOG is also subject to certain annual covenants under the Master Trust Indenture, the most restrictive is the Annual Debt Service Coverage Ratio (1.10x).

(1) Series 2018A and Series 2018B Revenue Bonds

The DHOG issued NHHEFA Revenue Bonds, Series 2018A and Series 2018B, in February 2018. The Series 2018A revenue bonds mature in variable amounts through 2037 and were used primarily to refund a portion of Series 2015A and Series 2016A revenue bonds. The Series 2018B revenue bonds mature in variable amounts through 2048, and were used primarily to refund a portion of Series 2015A and Series 2016A revenue bonds, revolving line of credit, Series 2012 bank loan, and the Series 2015A and Series 2016A swap terminations. The interest on the Series 2018A revenue bonds is variable, with a current interest rate of 5.00%. The interest on the Series 2018B revenue bonds is fixed, with an interest rate of 4.18%, and matures in variable amounts through 2048.

(2) Series 2020A Revenue Bonds

The DHOG issued NHHEFA Revenue Bonds, Series 2020A, in February 2020. The Series 2020A revenue bonds mature in variable amounts through 2059 and the proceeds are being used primarily to fund the construction of a 212,000 square foot inpatient pavilion in Lebanon, NH, as well as various equipment. The interest on the Series 2020A revenue bonds is fixed, with an interest rate of 5.00%.

(3) Series 2017A and Series 2017B Revenue Bonds

The DHOG issued NHHEFA Revenue Bonds, Series 2017A and Series 2017B, in December 2017. The Series 2017A revenue bonds mature in variable amounts through 2040 and were used primarily to refund Series 2009 and Series 2010 revenue bonds. The Series 2017B revenue bonds mature in variable amounts through 2031 and were used to refund Series 2012A and Series 2012B revenue bonds. The interest on the Series 2017A revenue bonds is fixed, with an interest rate of 5.00%. The interest on the Series 2017B revenue bonds is fixed, with an interest rate of 2.54%.

(4) Series 2019A Revenue Bonds

The DHOG issued NHHEFA Revenue Bonds, Series 2019A, in October 2019. The Series 2019A revenue bonds mature in variable amounts through 2043 and were used primarily to fund the construction of a 91,000 square foot expansion of facilities in Manchester, NH, to include an Ambulatory Surgical Center as well as various equipment. The interest on the Series 2019A revenue bonds is fixed, with an interest rate of 4.00%.

(5) Series 2018C Revenue Bonds

The DHOG issued NHHEFA Revenue Bonds, Series 2018C, in August 2018. The Series 2018C revenue bonds mature in variable amounts through 2030 and were used primarily to refinance

the Series 2010 revenue bonds. The interest on the Series is fixed, with an interest rate of 3.22%.

(6) Series 2012 Revenue Bonds

The DHOG issued NHHEFA Revenue Bonds, Series 2012, in November 2012. The Series 2012 revenue bonds mature in variable amounts through 2039 and were used to refund 1998 and 2009 Series revenue bonds, finance the settlement cost of the interest rate swap, and finance the purchase of certain equipment and renovations. The revenue bonds have fixed interest coupon rates ranging from 2.0% to 5.0% (a net interest cost of 3.96%).

(7) Series 2014A and Series 2014B Revenue Bonds

The DHOG issued NHHEFA Revenue Bonds, Series 2014A and Series 2014B, in August 2014. The Series 2014A revenue bonds mature in 2022. The Series 2014B revenue bonds mature at various dates through 2033. The proceeds from the Series 2014A and 2014B revenue bonds were used partially to refund the Series 2009 revenue bonds and to cover cost of issuance. Interest on the 2014A revenue bonds is fixed, with an interest rate of 2.63%. Interest on the Series 2014B revenue bonds is fixed, with an interest rate of 4.00%.

(8) Series 2016B Revenue Bonds

The DHOG issued NHHEFA Revenue Bonds, Series 2016B, in July 2016, through a private placement with a financial institution. The Series 2016B revenue bonds mature at various dates through 2045 and were used to finance certain 2016 projects. The Series 2016B is fixed, with an interest rate of 1.78%.

(9) Note payable to financial institution

The DHOG issued a note payable to TD Bank in May 2020. Issued in response to the COVID-19 pandemic, the proceeds from the note will be used to fund working capital, as needs require. The note matures at various dates through 2035 and is fixed, with an interest rate of 2.56%.

Outstanding joint and several indebtedness of the DHOG at June 30, 2022 and 2021 is \$1,044,722 and \$1,053,637, respectively.

The Health System indenture agreements require establishment and maintenance of debt service reserves and other trustee held funds. Trustee held funds of \$99,397,000 and \$170,399,000 at June 30, 2022 and 2021, respectively, are classified as assets limited as to use in the accompanying Consolidated Balance Sheets (Note 5). In addition, debt service reserves of approximately \$6,674,000 and \$8,035,000 at June 30, 2022 and 2021, respectively, are classified as other current assets in the accompanying Consolidated Balance Sheets. The debt service reserves are mainly comprised of escrowed construction funds at June 30, 2022 and 2021.

For the years ended June 30, 2022 and 2021 interest expense on the Health System's long-term debt is reflected in the accompanying Consolidated Statements of Operations and Changes in Net Assets as operating expense of approximately \$32,113,000 and \$30,787,000, respectively, and other non-operating losses of \$3,782,000 and \$3,782,000, respectively, net of amounts capitalized.

11. Employee Benefits

Eligible employees of the Health System are covered under various defined benefit and/or defined contribution plans. In addition, certain members provide postretirement medical and life insurance benefit plans to certain active and former employees who meet eligibility requirements. The postretirement medical and life plans are not funded.

The Health System's defined benefit plans have been frozen and, therefore, there are no remaining participants earning benefits in any of the Health System's defined benefit plans.

For the year ended June 30, 2021, the Health System executed the settlement of obligations, due to retirees in the defined benefit plans, through bulk lump sum offerings or purchases of annuity contracts. The annuity purchases follow guidelines established by the Department of Labor (DOL). The Health System anticipates continued consideration and/or implementation of additional settlements over the next several years.

Defined Benefit Plans

Net periodic pension expense included in employee benefits expense, in the Consolidated Statements of Operations and Changes in Net Assets, is comprised of the following components for the years ended June 30, 2022 and 2021:

(in thousands of dollars)	<u>2022</u>	<u>2021</u>
Interest cost on projected benefit obligation	\$ 36,722	\$ 36,616
Expected return on plan assets	(65,917)	(63,261)
Net loss amortization	13,139	14,590
Total net periodic pension expense	\$ (16,056)	\$ (12,055)

The following assumptions were used to determine net periodic pension expense as of June 30, 2022 and 2021:

	<u>2022</u>	<u>2021</u>
Discount rates	3.30%	3.00 - 3.10%
Rate of increase in compensation	N/A	N/A
Expected long-term rates of return on plan assets	7.50%	7.50%

The following table sets forth the funded status and amounts recognized in the Health System's consolidated financial statements for the defined benefit pension plans at June 30, 2022 and 2021:

(in thousands of dollars)	<u>2022</u>			<u>2021</u>		
Change in benefit obligation						
Benefit obligation, beginning of year	\$	1,140,221	\$	1,209,100		
Interest cost		36,722		36,616		
Benefits paid		(54,864)		(52,134)		
Actuarial loss		(183,193)		(22,411)		
Settlements		-		(30,950)		
Benefit obligation, end of year		938,886		1,140,221		
Change in plan assets						
Fair value of plan assets, beginning of year		958,864		929,453		
Actual return on plan assets		(169,405)		87,446		
Benefits paid		(54,864)		(52,134)		
Employer contributions		12,500		25,049		
Settlements		-		(30,950)		
Fair value of plan assets, end of year		747,095		958,864		
Funded status of the plans		(191,791)		(181,357)		
Less: Current portion of liability for pension				(46)		
Long-term portion of liability for pension		(191,791)		(181,311)		
Liability for pension	\$	(191,791)	\$	(181,357)		

As of June 30, 2022 and 2021, the liability for pension is included in the liability for pension and other postretirement plan benefits in the accompanying Consolidated Balance Sheets.

Amounts not yet reflected in net periodic pension expense and included in the change in net assets without donor restrictions include \$519,946,000 and \$481,073,000 of net actuarial loss as of June 30, 2022 and 2021, respectively.

The estimated amounts to be amortized from net assets without donor restrictions into net periodic pension expense in fiscal year 2022 for net actuarial losses is \$13,139,000.

The accumulated benefit obligation for the defined benefit pension plans was \$939,000,000 and \$1,140,000,000 at June 30, 2022 and 2021, respectively.

The following table sets forth the assumptions used to determine the accumulated benefit obligation at June 30, 2022 and 2021:

	<u>2022</u>	<u>2021</u>
Discount rates	4.40 - 5.10%	3.30%
Rate of increase in compensation	N/A	N/A

The primary investment objective for the defined benefit plans' assets is to support the pension liabilities of the pension plans for employees of the Health System, by providing long-term capital appreciation and by also using a Liability Driven Investing ("LDI") strategy to partially hedge the impact fluctuating interest rates have on the value of the pension plan's liabilities. As of June 30, 2022, it is expected that the LDI strategy will hedge approximately 70% of the interest rate risk associated with pension liabilities. As of June 30, 2021, the expected LDI hedge was approximately 75%. To achieve the appreciation and hedging objectives, the pension plans utilize a diversified structure of asset classes. The asset classes are designed to achieve stated performance objectives, measured on a total return basis which includes income plus realized and unrealized gains and losses.

The range of target allocation percentages and the target allocations for the various investments are as follows:

	Range of Target <u>Allocations</u>	Target <u>Allocations</u>
Cash and short-term investments	0–5%	3%
U.S. government securities	0–10	5
Domestic debt securities	20–58	42
Global debt securities	6–26	4
Domestic equities	5–35	17
International equities	5–15	7
Emerging market equities	3–13	4
Global Equities	0-10	6
Real estate investment trust funds	0–5	1
Private equity funds	0–5	0
Hedge funds	5–18	11

To the extent an asset class falls outside of its target range on a quarterly basis, the Health System shall determine appropriate steps, as it deems necessary, to rebalance the asset class.

The Boards of Trustees of the Health System, as plan sponsors, oversee the design, structure, and prudent professional management of the Health System's pension plans' assets, in accordance with Board approved investment policies, roles, responsibilities, and authorities and more specifically the following:

- Establishing and modifying asset class targets with Board approved policy ranges,
- Approving the asset class rebalancing procedures,
- Hiring and terminating investment managers, and
- Monitoring performance of the investment managers, custodians and investment consultants.

The hierarchy and inputs to valuation techniques to measure fair value of the Plans' assets are the same as outlined in Note 7. In addition, the estimation of fair value of investments in private equity and hedge funds for which the underlying securities do not have a readily determinable value is made using the NAV per share or its equivalent as a practical expedient. The Health System's pension plans own interests in both private equity and hedge funds rather than in securities underlying each fund and, therefore, the Health System generally considers such investments as Level 3, even though the underlying securities may not be difficult to value or may be readily marketable.

The following table sets forth the Health System's pension plans' investments and deferred compensation plan assets that were accounted for at fair value as of June 30, 2022 and 2021:

	2022						
(in thousands of dollars)	Level 1	Level 2	Level 3	<u>Total</u>	Redemption or Liquidation	Days' <u>Notice</u>	
Investments							
Cash and short-term investments	\$-	\$ 16,030	\$-	\$ 16,030	Daily	1	
U.S. government securities	124,686	-	-	124,686	Daily–Monthly	1–15	
Domestic debt securities	17,530	226,107	-	243,637	Daily–Monthly	1–15	
Global debt securities	-	24,136	-	24,136	Daily-Monthly	1–15	
Domestic equities	104,070	31,324	-	135,394	Daily-Monthly	1–10	
International equities	15,558	20,406	-	35,964	Daily-Monthly	1–11	
Emerging market equities	-	25,487	-	25,487	Daily-Monthly	1–17	
Global equities	-	54,787	-	54,787	Daily-Monthly	1–17	
REIT funds	-	-	-	-	Daily-Monthly	1–17	
Private equity funds	-	-	14	14	See Note 5	See Note 5	
Hedge funds			86,960	86,960	Quarterly–Annual	60–96	
Total investments	\$ 261,844	\$ 398,277	\$ 86,974	\$747,095			

				2021		
(in thousands of dollars)	Level 1	Level 2	Level 3	<u>Total</u>	Redemption or Liquidation	Days' <u>Notice</u>
Investments						
Cash and short-term investments	\$-	\$ 53,763	\$-	\$ 53,763	Daily	1
U.S. government securities	52,945	-	-	52,945	Daily-Monthly	1–15
Domestic debt securities	140,029	296,709	-	436,738	Daily-Monthly	1–15
Global debt securities	-	40,877	-	40,877	Daily-Monthly	1–15
Domestic equities	144,484	40,925	-	185,409	Daily-Monthly	1–10
International equities	17,767	51,819	-	69,586	Daily-Monthly	1–11
Emerging market equities	-	43,460	-	43,460	Daily-Monthly	1–17
Global equities	-	57,230	-	57,230	Daily-Monthly	1–17
REIT funds	-	3,329	-	3,329	Daily-Monthly	1–17
Private equity funds	-	-	15	15	See Note 5	See Note 5
Hedge funds	-	-	15,512	15,512	Quarterly–Annual	60–96
Total investments	\$ 355,225	\$ 588,112	\$ 15,527	\$ 958,864		

The following tables present additional information about the changes in Level 3 assets measured at fair value for the years ended June 30, 2022 and 2021:

			2	022	
(in thousands of dollars)	Hec	lge Funds		ivate <u>y Funds</u>	Total
Beginning of year balances Purchases Sales Net unrealized losses	\$	15,512 81,400 (2,152) (7,800)	\$	15 - - (1)	\$ 15,527 81,400 (2,152) (7,801)
End of year balances	\$	86,960	\$	14	\$ 86,974
			2	021	
(in thousands of dollars)	<u>Hec</u>	lge Funds		ivate <u>y Funds</u>	<u>Total</u>
Beginning of year balances Sales Net unrealized gains (losses)	\$	47,351 (38,000) 6,161	\$	17 - (2)	\$ 47,368 (38,000) 6,159
End of year balances	\$	15,512	\$	15	\$ 15,527

The total aggregate net unrealized (losses) gains included in the fair value of the Level 3 investments as of June 30, 2022 and 2021 were approximately (\$543,000) and \$7,635,000, respectively. There were transfers out of Level 3 measurements during the years ended June 30, 2022 and 2021. The hedge funds' liquidation will be completed by the end of Fiscal Year 2023.

There were no transfers into and out of Level 1 and 2 measurements due to changes in valuation methodologies during the years ended June 30, 2022 and 2021.

The weighted average asset allocation, by asset category, for the Health System's pension plans is as follows at June 30, 2022 and 2021:

	<u>2022</u>	<u>2021</u>
Cash and short-term investments	2 %	6 %
U.S. government securities	17	5
Domestic debt securities	33	46
Global debt securities	3	4
Domestic equities	18	19
International equities	5	7
Emerging market equities	3	5
Global equities	7	6
Hedge funds	12	2
Total	100 %	100 %

The expected long-term rate of return on plan assets is reviewed annually, taking into consideration the asset allocation, historical returns on the types of assets held, and the current economic environment. Based on these factors, it is expected that the pension assets will earn an average of 7.50% per annum.

The Health System is expected to contribute approximately \$12,500,000 to the Plans in 2023 however actual contributions may vary from expected amounts.

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid for the years ending June 30 and thereafter:

(in thousands of do	ollars)	
2023	\$	124,252
2024		56,264
2025		57,774
2026		59,040
2027		60,176
2028 – 2032		310,262

The Cheshire Medical Center plan was terminated effective June 30, 2022, pending regulatory approvals. Following regulatory approval, the plan sponsor intends to distribute assets and settle plan obligations through a lump sum offering to active and terminated vested participants and a group annuity contract will be purchased for any participant that doesn't elect the lump sum, along with all participants currently in pay status. It is anticipated that benefits will be distributed by June 30, 2023. The benefit obligation for the plan reflects anticipated disbursement costs and a terminal cash contribution to fully fund benefits will be made at that time. The obligations reflect the cost of providing the lump sums and group annuity, described above, as well as administrative costs and a terminal contribution which will be necessary to fund all of the costs of terminating the plan. It is expected that the obligations will be settled by June 30, 2023 and the plan termination liability will reflect economic conditions, lump sum election rates and annuity pricing at that time. As a result, the final plan termination liability may be different from the amounts shown in this report.

Defined Contribution Plans

The Health System has an employer-sponsored 401(a) plan for certain of its members, under which the employer makes base match contributions based on specified percentages of compensation and employee deferral amounts. Total employer contributions to the plan of approximately \$64,946,000 and \$60,268,000 in 2022 and 2021, respectively, are included in employee benefits expenses in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

Various 403(b) and tax-sheltered annuity plans are available to employees of the Health System. Plan specifications vary by member and plan. No employer contributions were made to any of these plans in 2022 and 2021.

Postretirement Medical and Life Insurance Benefits

The Health System has postretirement medical and life insurance benefit plans covering certain of its active and former employees. The plans generally provide medical or medical and life insurance benefits to certain retired employees who meet eligibility requirements. The plans are not funded.

Net periodic postretirement medical and life benefit (income) cost is comprised of the components listed below for the years ended June 30, 2022 and 2021:

(in thousands of dollars)		<u>2021</u>	
Service cost	\$	456	\$ 533
Interest cost		1,394	1,340
Net prior service income		-	(3,582)
Net loss amortization		752	 738
Total	\$	2,602	\$ (971)

The following table sets forth the accumulated postretirement medical and life insurance benefit obligation amounts recognized in the Health System's consolidated financial statements at June 30, 2022 and 2021:

(in thousands of dollars)		<u>2022</u>		<u>2021</u>
Change in benefit obligation				
Accumulated benefit obligation, beginning of year	\$	46,863	\$	48,078
Service cost		456		533
Interest cost		1,394		1,340
Benefits paid		(3,401)		(3,439)
Actuarial loss		(4,964)		383
Employer contributions		(33)	-	(32)
Accumulated benefit obligation, end of year	-	40,315	-	46,863
Current portion of liability for postretirement				
medical and life benefits	\$	(3,500)	\$	(3,422)
Long-term portion of liability for				. ,
postretirement medical and life benefits	-	(36,815)	-	(43,441)
Funded status of the plans and liability for				
postretirement medical and life benefits	\$	(40,315)	\$	(46,863)

As of June 30, 2022 and 2021, the liability for postretirement medical and life insurance benefits is included in the liability for pension and other postretirement plan benefits in the accompanying Consolidated Balance Sheets.

Amounts not yet reflected in net periodic income for the postretirement medical and life insurance benefit plans, included in the change in net assets without donor restrictions, are as follows:

(in thousands of dollars)		<u>2022</u>	<u>2021</u>
Net actuarial loss	_	4,445	9,981
Total	\$	4,445	\$ 9,981

The estimated amount of net losses that will be amortized from net assets without donor restrictions into net periodic postretirement income in fiscal year 2023 is approximately \$62,000.

The following future benefit payments, which reflect expected future service, as appropriate, are expected to be paid for the years ending June 30, 2022 and thereafter:

(in thousands	of dollars)	
2023	\$	3,500
2024		3,721
2025		3,725
2026		3,720
2027		3,700
2028-2032		16,820

In determining the accumulated benefit obligation for the postretirement medical and life insurance plans, the Health System used a discount rates of 5.10% in 2022, and an assumed healthcare cost trend rate of 7.00%, trending down to 5.00% in 2029 and thereafter.

12. Professional and General Liability Insurance Coverage

D-H, along with Dartmouth College, Cheshire, NLH, APD, MAHHC, and VNH are provided professional and general liability insurance on a claims-made basis through Hamden Assurance Risk Retention Group, Inc. (RRG), a VT captive insurance company. RRG cedes the majority of this risk to Hamden Assurance Company Limited (HAC), a captive insurance company domiciled in Bermuda, and HAC cedes a portion of this risk to a variety of commercial reinsurers. D-H has majority ownership interest in both HAC and RRG. The insurance program provides coverage to the covered institutions, named insureds and their employees on a modified claims-made basis, which means coverage is triggered when claims are made. Premiums and related insurance deposits are actuarially determined, based on asserted liability claims adjusted for future development. The reserves for outstanding losses are recorded on an undiscounted basis.

Selected financial data of HAC and RRG, taken from the latest available financial statements at June 30, 2022 and 2021, are summarized as follows:

		2022	
	HAC	<u>RRG</u>	<u>Total</u>
(in thousands of dollars)			
Assets	\$ 79,831	\$ 2,245	\$ 82,076
Shareholders' equity	13,620	50	13,670
		2021	
	HAC	RRG	Total
(in thousands of dollars)			
Assets	\$ 71,772	\$ 3,583	\$ 75,355
Shareholders' equity	13,620	50	13,670

13. Commitments and Contingencies

Litigation

The Health System is involved in various malpractice claims and legal proceedings of a nature considered normal to its business. The claims are in various stages and some may ultimately be brought to trial. While it is not feasible to predict or determine the outcome of any of these claims, it is the opinion of management that the final outcome of these claims will not have a material effect on the consolidated financial position of the Health System.

Line of Credit

The Health System has entered into a loan agreement with a financial institution, establishing access to revolving loans ranging from \$10,000,000 up to \$30,000,000. Interest is variable and determined using the Bloomberg Short-Term Bank Yield Index or the Wall Street Journal Prime Rate. The loan agreement is due to expire March 29, 2023. There was no outstanding balance under the line of credit as of June 30, 2022 and 2021. Interest expense was approximately \$91,000 and \$28,000, respectively, and is included in the Consolidated Statements of Operations and Changes in Net Assets.

14. Functional Expenses

Operating expenses are presented by functional classification in accordance with the overall service missions of the Health System. Each functional classification displays all expenses related to the underlying operations by natural classification. Salaries, employee benefits, medical supplies and medications, and purchased services and other expenses are generally considered variable and are allocated to the mission that best aligns to the type of service provided. Medicaid enhancement tax is allocated to program services. Interest expense is allocated based on usage of debt-financed space. Depreciation and amortization is allocated based on square footage and specific identification of equipment used by department.

Operating expenses of the Health System by functional and natural basis are as follows for the year ended June 30, 2022:

	2022							
(in thousands of dollars)	Program <u>Services</u>	Management and General		• •		<u>Fundraising</u>		Total
Operating expenses								
Salaries	\$ 1,129,572	\$	184,533	\$	1,302	\$ 1,315,407		
Employee benefits	281,455		40,887		228	322,570		
Medical supplies and medications	645,437		3,835		-	649,272		
Purchased services and other	255,639		142,241		5,982	403,862		
Medicaid enhancement tax	82,725		-		-	82,725		
Depreciation and amortization	42,227		44,675		56	86,958		
Interest	9,116		22,987		10	32,113		
Total operating expenses	\$ 2,446,171	\$	439,158	\$	7,578	\$ 2,892,907		

	Program Management <u>Services</u> <u>and General</u>		<u>Fund</u>	raising	<u>Total</u>		
Non-operating income Employee benefits	\$	12,144	\$ 1,755	\$	11	\$	13,910
Total non-operating income	\$	12,144	\$ 1,755	\$	11	\$	13,910

Operating expenses of the Health System by functional and natural basis are as follows for the year ended June 30, 2021:

	2021						
(in thousands of dollars)	Program <u>Services</u>	Management and General		Total			
Operating expenses							
Salaries	\$ 1,019,272	\$ 164,937	' \$ 1,701	\$ 1,185,910			
Employee benefits	212,953	88,786	6 403	302,142			
Medical supplies and medications	540,541	4,982		545,523			
Purchased services and other	252,705	125,931	5,313	383,949			
Medicaid enhancement tax	72,941	-		72,941			
Depreciation and amortization	38,945	49,943	3 33	88,921			
Interest	8,657	22,123	3 7	30,787			
Total operating expenses	\$ 2,146,014	\$ 456,702	2 \$ 7,457	\$ 2,610,173			
	Program Services	Management		Total			

	Se	ervices	and	General	Fund	raising	<u>Total</u>
Non-operating income							
Employee benefits	\$	9,200	\$	4,354	\$	5	\$ 13,559
Total non-operating income	\$	9,200	\$	4,354	\$	5	\$ 13,559

15. Liquidity

The Health System is substantially supported by cash generated from operations. In addition, the Health System holds financial assets for specific purposes which are limited as to use. Thus, certain financial assets reported on the accompanying Consolidated Balance Sheets may not be available for general expenditure within one year of the balance sheet date.

The Health System's financial assets available at June 30, 2022 and 2021 to meet cash needs for general expenditures within one year of June 30, 2022 and 2021, are as follows:

(in thousands of dollars)	<u>2022</u>	<u>2021</u>
Cash and cash equivalents Patient accounts receivable Assets limited as to use Other investments for restricted activities	\$ 191,929 251,250 1,181,094 175,116	\$ 374,928 232,161 1,378,479 168,035
Total financial assets	\$ 1,799,389	\$ 2,153,603
Less: Those unavailable for general expenditure within one year: Investments held by captive insurance companies Investments for restricted activities Bond proceeds held for capital projects	57,522 175,116 99,397	57,239 168,035 178,434
Other investments with liquidity horizons greater than one year Total financial assets available within one year	\$ <u>159,792</u> 1,307,562	\$ <u>111,390</u> 1,638,505

The Health System generated cash flow from operations of approximately \$(123,525,000) and \$95,740,000 for the years ended June 30, 2022 and June 30, 2021, respectively. In addition, the Health System's liquidity management plan includes investing excess daily cash in intermediate or long term investments based on anticipated liquidity needs. The Health System has an available line of credit of up to \$30,000,000 which it can draw upon as needed to meet its liquidity needs. See Note 13 for further details on the line of credit.

16. Lease Commitments

D-HH determines if an arrangement is or contains a lease at inception of the contract. Right-of-use assets represent our right to use the underlying assets for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right-of-use assets and lease liabilities are recognized at commencement date, based on the present value of lease payments over the lease term. The Health System uses the implicit rate noted within the contract. If not readily available, the Health System uses an estimated incremental borrowing rate, which is derived using a collateralized borrowing rate, for the same currency and term, as the associated lease. A right-of-use asset and lease liability is not recognized for leases with an initial term of 12 months or less, rather the Health System recognizes lease expense for these leases on a straight-line basis, over the lease term, within lease and rental expense.

Operating leases are primarily for real estate, including certain acute care facilities, off-campus outpatient facilities, medical office buildings, and corporate and other administrative offices. Real estate lease agreements typically have initial terms of 5 to 10 years. These real estate leases may include one or more options to renew, with renewals that can extend the lease term from 2 to 5 years. The exercise of lease renewal options is at the Health System's sole discretion. When

determining the lease term, management includes options to extend or terminate the lease when it is reasonably certain that the Health System will exercise that option.

Certain lease agreements for real estate include payments based on actual common area maintenance expenses and/or rental payments adjusted periodically for inflation. These variable lease payments are recognized in other occupancy costs in the Consolidated Statements of Operations and Changes in Net Assets, but are not included in the right-of-use asset or liability balances in our Consolidated Balance Sheets. Lease agreements do not contain any material residual value guarantees, restrictions, or covenants.

The components of lease expense for the years ended June 30, 2022 and 2021 are as follows:

(in thousands of dollars)	<u>2022</u>	<u>2021</u>
Operating lease cost Variable and short term lease cost (a)	\$ 9,573 10,894	\$ 10,381 8,019
Total lease and rental expense	\$ 20,467	\$ 18,400
Finance lease cost: Depreciation of property under finance lease Interest on debt of property under finance lease	\$ 3,345 448	\$ 3,408 533
Total finance lease cost	\$ 3,793	\$ 3,941

(a) Includes equipment, month-to-month and leases with a maturity of less than 12 months.

Supplemental cash flow information related to leases for the years ended June 30, 2022 and 2021 are as follows:

(in thousands of dollars)	<u>2022</u>	<u>2021</u>
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases	\$ 9,952	\$ 10,611
Operating cash flows from finance leases	448	533
Financing cash flows from finance leases	 3,255	 3,108
Total	\$ 13,655	\$ 14,252

Supplemental balance sheet information related to leases as of June 30, 2022 and 2021 are as follows:

(in thousands of dollars)	<u>2022</u>	<u>2021</u>
Operating Leases Right-of-use assets - operating leases Accumulated amortization	\$ 61,165 (21,222)	\$ 51,410 (15,180)
Right-of-use assets - operating leases, net	 39,943	36,230
Current portion of right-of-use obligations Long-term right-of-use obligations, excluding current portion Total operating lease liabilities	 8,314 32,207 40,521	 8,038 28,686 36,724
Finance Leases Right-of-use assets - finance leases Accumulated depreciation Right-of-use assets - finance leases, net	 27,963 (8,981) 18,982	 27,940 (5,760) 22,180
Current portion of right-of-use obligations Long-term right-of-use obligations, excluding current portion	3,005 16,617	 3,251 19,481
Total finance lease liabilities	\$ 19,622	\$ 22,732
Weighted Average remaining lease term, years Operating leases Finance leases	7.73 19.77	6.75 18.73
Weighted Average discount rate Operating leases Finance leases	2.24% 2.17%	2.12% 2.14%

The System obtained \$8.9 million and \$0.1 million of new and modified operating and financing leases, respectively, during the year ended June 30, 2022.

The System obtained \$7.6 million and \$2.1 million of new and modified operating and financing leases, respectively, during the year ended June 30, 2021.

Future maturities of lease liabilities as of June 30, 2022 are as follows:

(in thousands of dollars)	<u>Opera</u>	ting Leases	Finar	nce Leases
Year ending June 30:				
2023	\$	9,121	\$	3,395
2024		7,971		2,297
2025		5,083		1,261
2026		3,750		882
2027		3,357		800
Thereafter		15,096		15,713
Total lease payments		44,378		24,348
Less: Imputed interest		3,857		4,726
Total lease obligations	\$	40,521	\$	19,622

17. Subsequent Events

The Health System has assessed the impact of subsequent events through November 16, 2022, the date the audited consolidated financial statements were issued, and has concluded that there were no such events that require adjustment to the audited consolidated financial statements or disclosure in the notes to the audited consolidated financial statements.

Consolidating Supplemental Information

Dartmouth-Hitchcock Health and Subsidiaries Consolidating Balance Sheets June 30, 2022
Dartm Consol June 3(

ated All Other Non- o Oblig Group System <u>al Affiliates Eliminations Consolidated</u>	167,258 \$ 24,671 \$ - \$ 191,929 248,858 2.392 - 251,260 182,730 (11,372) (2,225) 169,133	598,846 15,691 (2,225) 612,312	,130,174 50,920 - 1,181,094 803 (803)	ο n	(2,168)	\$ 122,822 \$ (2,225) \$ 2;	6,498 \$ 98 \$ - \$ 6,596 11,259 60 - 11,319	' ' ୯୦୦ ୦୦ ୦୦	102,193 0,002 (2,220) 100,500 189,383 1,177 - 190,560 134,898 - 134,898	7,337 (2,225)			228,605 - 228,606 132,250 21,846 - 154,096	2,101,070 31,805 (2,225) 2,130,650	580,905 53,352 40 634,297 161,878 37,665 (40) 199,503	
DH Obligated Group Eliminations Subtotal	\$ - \$ 167 - 248 (31,119) 182	(31,119) 598	(98,848) 1,130 (853,609)		174	\$ (983,576) \$ 2,843	8 		- 134 - 180 - 134	(129,967) 498	(853,609) - 1,114 - 46	- 78	- 228	(983,576) 2,101	- 580	
Mt. Ascutney Hospital and <u>Health Center</u>	7 \$ 11,327 5 5,360 2 1,472	1	5 25,753 	5 6,846 3 15.526		6 \$ 76,516	3 \$ - 2 473	- cc3 a		1 14,247	7 17,570 2 (110) - 4.885		- 481 9 -	0 37,323	4 31,078 8.115	
sck New London Hospital <u>al</u> <u>Association</u>	38,416 \$ 28,467 9,817 9,175 9,175 3,522 4,452	51,755 42,094	14,680 16,005 803 -	727 3,925 24.757 45.973		\$ 11	800 \$ 23 852 172		4,003 4,043 4,431 4,507 17,488 21,886		- 27,437 23,060 32 14 499 -	373 401	- 300	66,686 61,050	54,590 48,974 729 4.712	
Cheshire Alice Peck Medical Day <u>Center Memorial</u>	20,165 \$ 38 18,106 \$ 5 19,580	57,851 51	12,665 14 -	16,422 63.067 24		153,022 \$ 122	865 8965 89		6,817 4 22,999 17			623	7,774 1,109	80,583 66	53,646 546 18.793	
Dartmouth- Mitchcock	\$ 66,827 \$ 206,400 161,262	434,489	858,919 11,557	118,082 585.064		\$ 2,189,948 \$	\$ 4,810 \$ 8,514	3,500	100,110 169,194 68,876	355,004	808,602 25,084 27,359	76,678	220,350 129,092	1,642,169	418,255 129,524	
Dartmouth - Hitchcock <u>Health</u>	\$ 2,056 { - 23,561	25,617	301,000 842,052	490	1,362 681	\$ 1,171,202	ی ی ی ک		147,020 - 3,002	151,187	- 1,044,845 803			1,196,835	(25,638) 5	
(in thousands of dollars)	Assets Current assets Cash and cash equivalents Patient accounts receivable, net Prepaid expenses and other current assets	Total current assets	Assets limited as to use Notes receivable, related party	Other investments for restricted activities Property. plant. and equipment. net	Right-of-use assets, net Other assets	Total assets	Liabilities and Net Assets Current liabilities Current portion of long-term debt Current portion of right-of-use obligations	Current portion of liability for pension and other postretirement plan benefits	Accounts payable and accured expenses Accrued compensation and related benefits Estimated third-party settlements	Total current liabilities	Notes payable, related party Long-term debt, excluding current portion Richt-of-use oblications excluding current nortion	Insurance deposits and related liabilities	Labuility for pension and other postreurement plan benefits, excluding current portion Other liabilities	Total liabilities	Commitments and contingencies Net assets Net assets without donor restrictions Net assets with donor restrictions	

51

	an	D-HH and Other		D-H and	Che	Cheshire and			MAH	MAHHC and	AF	APD and	~	VNH and	i		Sys He	Health System
(in thousands of dollars)	Sub	Subsidiaries	ns.	Subsidiaries		Subsidiaries		NLH	Subs	Subsidiaries		Subsidiary	Sub	Subsidiaries	Ē	Eliminations	Conso	Consolidated
Current assets	e	0.00	e	00 075	e	201500	e	201 00	e	10011	e	100 21	e	000	e		e	
Cash and cash equivalents Patient accounts receivable, net	9	ocn'z	9	206,400	9	18,106	Ð	9,175	9	5,431	Ð	47,034 9,817	9	2,321	9			191,929 251,250
Prepaid expenses and other current assets		23,561		161,508		8,296		4,452		1,499		2,678		483		(33,344)		169,133
Total current assets		25,617		435,983		58,902		42,094		18,561		60,389		4,110		(33,344)	•	612,312
Assets limited as to use		301,000		884,007		13,183		16,005		26,979		14,680		24,088		(98,848)	÷	1,181,094
Notes receivable, related party		842,052		11,557				- 100 0				' rco r		' 0	-	(853,609)	-	
Other investments for restricted activities Property, plant, and equipment, net		430		587.739		57,124 66.385		3,923 45.973		0,040 16.947		42.436		00 5.360				764.840
Right-of-use assets, net		1,362		35,321		1,830		166		5,248		14,892		106		•		58,925
Other assets		681		146,699		8,316		6,573		2,526		7,292		76		·		172,163
Total assets	ф	1,171,202	ŝ	2,226,920	ŝ	185,740	ф	114,736	ŝ	77,107	φ	140,720	ф	33,826	ŝ	(985,801)	\$ 2,9	2,964,450
Liabilities and Net Assets																		
Current portion of long-term debt	ഗ	'	ŝ	4,810	ŝ	865	ŝ	23	ŝ	26	ക	800	ക	72	ŝ	,	ŝ	6,596
Current portion of right-of-use obligations		559		8,514		689		172		472		852		61		•		11,319
Current portion of liability for pension and				2 600														2 600
Accounts positionille in pian benefits		- 117 676		3,300 100 617		-		- 1 8/2		- 58 8		5 AB1		- 1640		- 132 102)		0,000 166 670
Accounts payable and acclued expenses Accrited compensation and related henefits				169 194		6 817		4,043		0,001 4 490		0,401 4 735		4,040 817	-	(1361,1361) -	-	190,560
Estimated third-party settlements		3,002		68,876		22,999		21,886		647		17,488		. '			-	134,898
Total current liabilities		151,187		355,511		48,096		31,431		14,466		29,356		5,590		(132, 192)		503,445
Notes payable, related party		'		808,602				27,437		17,570		'				(853,609)		'
Long-term debt, excluding current portion		1,044,845		25,084		21,867		32		110		23,005		2,345		•	,	1,117,288
Right-of-use obligations, excluding current portion	_	803		27,359		1,233		' !		4,885		14,499		45		•		48,824
Insurance deposits and related liabilities				/6,6/8		623		401		250		3/3		99				/8,391
Liability for pension and other postreurement plan benefits, excluding current portion		'		220,350		7,774		'		482				,				228,606
Other liabilities		•		129,092		1,109		1,749				22,146				•		154,096
Total liabilities		1,196,835		1,642,676		80,702		61,050		37,763		89,379		8,046		(985,801)	2,	2,130,650
Commitments and contingencies																		
Net assets								120.01										
Net assets without donor restrictions Net assets with donor restrictions		(20,030) 5		447,013 137,231		20,014 48,364		40,974 4,712		31,231 8,113		ou, suo 1, 033		∠0,090 85		40 (40)		034,297 199,503
Total net assets		(25,633)		584,244		105,038		53,686		39,344		51,341		25,780				833,800
Total liabilities and net assets	ф	1,171,202	ф	2,226,920	φ	185,740	ф	114,736	ŝ	77,107	ŝ	140,720	ŝ	33,826	\$	(985,801)	\$ 2,9	2,964,450

Dartmouth-Hitchcock Health and Subsidiaries Consolidating Balance Sheets June 30, 2022

52

Dartmouth-Hitchcock Health and Subsidiaries Consolidating Balance Sheets June 30, 2021	k Healtl Sheets	h and Su	bsidiar	es							
(in thousands of dollars)	Dartmouth- Hitchcock <u>Health</u>	Dartmouth- <u>Hitchcock</u>	Cheshire Medical <u>Center</u>	Alice Peck Day <u>Memorial</u>	New London Hospital <u>Association</u>	Mt. Ascutney Hospital and <u>Health Center</u>	Eliminations	DH Obligated Group <u>Subtotal</u>	All Other Non- Oblig Group <u>Affiliates</u>	Eliminations	Health System <u>Consolidated</u>
Assets Current assets Cash and cash equivalents Patient accounts receivable, net Prepaid expenses and other current assets Total current assets	\$ 1,826 - 23,267 25,093	\$ 226,779 196,350 151,336 574,465	\$ 35,146 13,238 20,932 69,316	\$ 41,371 6,779 2,012 50,162	\$ 26,814 6,699 4,771 38,284	\$ 18,350 6,522 1,793 26,665	\$ - (35,942) (35,942)	\$ 350,286 229,588 168,169 748,043	\$ 24,642 2,573 (10,634) 16,581	\$ - (217) (217)	\$ 374,928 232,161 157,318 764,407
Assets limited as to use the party Notes receivable, related party Other rinvestments for restricted activities Property, plant, and equipment, net Right-of-use assets Other assets	380,020 845,157 248 1,233 2,431	1,039,327 1,039,327 111,769 111,209 501,640 32,343 146,229	19,016 19,016 64,101 2,396 1,315	15,480 15,480 1,010 1,128 2,2623 16,104 16,104 16,104	e			τ, c	57,565 (1,010) 31,273 29,434 155 292		÷ (
I oral assets Liabilities and Net Assets Current liabilities Current portion of long-lerm debt Current portion of right-of-use obligations Current portion of liability for pension and other postretirement plan benefits Accounts payable and accrued expenses Accounts payable and accrued expenses Accounts payable and accrued expenses Estimated third-party settlements	3 1,234,162 5 354 207,566		\$ 100,550 656 11,911 8,648 31,226	\$ 120,087 \$ 1,078 1,078 2,455 5,706 2,706	- • • •	\$ 00,355 550 5,858 5,343 6,230	\$ (1,062,717) 5 - 	 5,092,789 9,308 11,204 3,468 3,468 126,341 180,177 251,774 	\$ 134,290 \$ 85 5,100 1,893 769	\$ (217) 	 5,226,802 9,407 11,289 3,468 131,224 182,070 252,543
Total current liabilities Notes payable, related party Long-term debt, excluding current portion Right-of-use obligations, excluding current portion Insurance deposits and related liabilities Liability for pension and other postretirement plan benefits, excluding current portion Other liabilities	207,920 - 879 - -	435,269 811,563 29,846 24,463 78,528 78,528 218,955 179,497	53,306 22,753 1,876 475 5,286 4,224	37,022 - 23,558 15,351 325 325 4,534	36,565 26,7,793 55 172 388 388 388 4,142	17,981 17,570 (115) 5,357 218 511	(205,791) (856,926) - - -	582,272 - 1,123,756 48,098 79,934 224,752 192,397	7,946 - 2,601 69 40 - 22,317	(217) - - - - -	590,001 - 1,126,357 48,167 79,974 79,974 224,752 214,714
Total liabilities Commitments and contingencies Net assets Net assets without donor restrictions Net assets with donor restrictions Total net assets Total liabilities and net assets	1,256,458 (2,524) 248 (2,276) \$ 1,254,182	1,778,121 526,153 112,705 638,858 \$2,416,979 \$2,416,979	87,920 65,224 15,212 80,436 \$ 168,356	80,790 38,969 1,128 40,097 \$ 120,887	69,115 39,557 5,477 5,477 8 114,149	41,522 29,838 9,593 39,431 \$ 80,953	(1,062,717) - - - - - -	2,251,209 697,217 144,363 841,580 \$ 3,092,789	32,973 61,370 39,947 39,947 101,317 \$ 134,290	(217) 40 (40) \$ (217)	2,283,965 758,627 184,270 942,897 \$ 3,226,862

(in thousands of dollars)	D- and c	D-HH and Other Subsidiaries	D-F	D-H and Subsidiaries	Ches Sub:	Cheshire and Subsidiaries	NI Sub	NLH and Subsidiaries	MAI Sub	MAHHC and Subsidiaries	AP Sub	APD and Subsidiary	Subs	VNH and Subsidiaries	Elin	Eliminations	Cons	Health System Consolidated
ssets rrrent assets Cash and cash equivalents Patient accounts receivable, net Prepaid expenses and other current assets	ŝ	1,826 - 23,267	\$	227,402 196,350 151,677	ନ	44,165 13,238 10,195	ŝ	26,814 6,699 4,771	Ŷ	18,609 6,620 1,808	θ	50,451 6,779 1,418	ŝ	5,661 2,475 341	Ŷ	- - (36,159)	÷	374,928 232,161 157,318
Total current assets		25,093		575,429		67,598		38,284		27,037		58,648		8,477		(36, 159)		764,407
Assets limited as to use Notes receivable, related party		380,020 845,157	-	,066,781 11,769		20,459 -		16,725 -		21,533 -		15,480 -		27,330 -		(169,849) (856,926)		1,378,479 -
Other investments for restricted activities		248		119,371 504 245		34,921 67 643		4,266		7,698 16.022		1,501		30				168,035 600 422
Property, plant, and equipment, met Right-of-use assets, net Other assets		- 1,233 2,431		32,343 32,343 146 408		01, 345 2, 396 10 286		41,232 360 7 282		5,820 5,820 2715		41,210 16,104 7534		0,130 154 442				58,410 58,410 177 098
Total assets	\$ 1,2	1,254,182	\$ 2	2,456,416	÷	203,203	ф	114,149	¢	81,735	ъ	140,485	\$	39,626	\$	(1,062,934)	ŝ	3,226,862
Liabilities and Net Assets Current liabilities Current portion of long-term debt Current portion of right-of-use obligations	ь	- 354	\$	7,575 8,369	ŝ	865 656	ŝ	91 197	\$	26 550	\$	777 1,078	ŝ	73 85	\$		\$	9,407 11,289
current portion of ilability for pension and other postretirement plan benefits		- - -		3,468 00.682		- 10 030		-		- 5 082		-		- 100 1		-		3,468 131 224
Accounts payable and account expenses Accrued compensation and related benefits Estimated third-party settlements	•			33,002 156,073 160,410		8,648 31,226		4,407 26,902		5,385 6,231		6,116 27,006		1,441 768				182,070 252,543
Total current liabilities		207,920		435,577		53,427		36,565		18,175		37,897		6,448		(206,008)		590,001
Notes payable, related party		-		811,563		- 750		27,793 55		17,570				' F F C		(856,926)		- 100 201 1
Right-of-use obligations, excluding current portion		879 879		24,463		1,876 1,876		172		5,357		15,351		- 4'4 69				48,167
Lisuance upposits and readed natifiers Lability for pension and other postretirement plan benefits, excluding current portion				218,955		5,286		0000 -		511 511								224,752
Other liabilities		'		179,497		4,223		4,142				26,852		'		'		214,714
Total liabilities	1,1	1,256,458	-	1,778,429		88,041		69,115		41,962		103,921		8,973	Ŭ	(1,062,934)		2,283,965
Commitments and contingencies																		
st assets Net assets without donor restrictions Net assets with donor restrictions		(2,524) 248		557,101 120,886		68,586 46,576		39,557 5,477		30,181 9,592		35,063 1,501		30,623 30		40 (40)		758,627 184,270
Total net assets		(2,276)		677,987		115,162		45,034		39,773		36,564		30,653		' 		942,897
Total liabilities and net assets	\$ 1,2	1,254,182	\$	2,456,416	Ь	203,203	ക	114,149	ф	81,735	ക	140,485	ь	39,626	ن بې	(1,062,934)	Ś	3,226,862

Consolidating Statements of Operations and Changes in Net Assets without Donor Restrictions Year Ended June 30, 2022 **Dartmouth-Hitchcock Health and Subsidiaries**

	Dartmouth-		Cheshire	Alice Peck	New London	Mt. Ascutney		DH Obligated	All Other Non-		Health
(in thousands of dollars)	Hitchcock <u>Health</u>	Dartmouth- <u>Hitchcock</u>	Medical Center	Day Memorial	Hospital Association	Hospital and Health Center	Eliminations	Group Subtotal	Oblig Group <u>Affiliates</u>	Eliminations	System Consolidated
Operating revenue and other support	e	\$ 1751093	\$ 236.645	\$ 99.403	\$ 79 754	\$ 59 D40	G	\$ 225 035	\$ 17 302	e	250 540 6 8
Contracted revenue	209 209				22	3,521		77,293			77,666
Other operating revenue	38,568	492,455	23,736	4,146	7,527	2,754	(50,711)	518,475	16,731	(1,175)	534,031
Net assets released from restrictions	249	13,299	577	435	190	204	'	15,156	738		15,894
Total operating revenue and other support	39,026	2,390,775	261,325	104,005	87,493	65,519	(111,284)	2,836,859	35,229	(1,260)	2,870,828
Operating expenses		1 001 601	126 002	220 01	010 01	090 00	(46 220)	1 202 000	201.02	1 005	1 315 107
Galaries Employee benefits		266.795	31.761	10.302	7.537	8.240	(5.842)	318.793	3.514	263	322.570
Medications and medical supplies		578,581	43,203	12,266	9,946	4,127		648,123	1,149		649,272
Purchased services and other	25,638	312,373	42,723	15,951	13,068	17,383	(32,862)	394,274	11,398	(1,810)	403,862
Medicaid enhancement tax		64,036	9,468	3,980	2,834	2,407		82,725			82,725
Depreciation and amortization	'	64,643	8,771	3,519	4,819	2,359		84,111	2,847	•	86,958
Interest	32,536	25,365	914	876	1,073	493	(29,530)	31,727	386	·	32,113
Total operating expenses	58,174	2,403,394	271,923	90,160	79,496	63,969	(113,463)	2,853,653	39,716	(462)	2,892,907
Operating (loss) margin	(19,148)	(12,619)	(10,598)	13,845	7,997	1,550	2,179	(16,794)	(4,487)	(798)	(22,079)
Non-operating (losses) gains Investment losses, net	(8,026)	(58,973)	(2,068)	(795)	(1,114)	(1,555)	(210)	(72,741)	(6,003)		(78,744)
Uther components of het periodic pension and post retirement benefit income		11,902	2,008				,	13,910			13,910
Other (losses) income, net	(3,540)	(1,641)	(542)		-	169	(1,969)	(7,522)	99	798	(6,658)
Total non-operating (losses) gains, net	(11,566)	(48,712)	(602)	(195)	(1,113)	(1,386)	(2,179)	(66,353)	(5,937)	798	(71,492)
(Deficiency) excess of revenue over expenses	(30,714)	(61,331)	(11,200)	13,050	6,884	164		(83,147)	(10,424)	ı	(93,571)
Net assets without donor restrictions Net assets released from restrictions for capital		678	52		460	233		1,423	150		1,573
Change in tunded status of pension and other postretirement benefits	- 000 F	(27,860)	(4,496)	- 12 0	' 900 c	48 705		(32,308)	(1)		(32,309)
Net assets transferred to (notif) anniates Other changes in net assets	-	(coc,eı) -	+,000		z,030 (23)	-		(23)	2,231		- (23)
(Decrease) increase in net assets without donor restrictions	\$ (23,114)	\$ (107,898)	\$ (11,578)	\$ 15,621	\$ 9,417	\$ 1,240	' \$	\$ (116,312)	\$ (8,018)	' ب	\$ (124,330)

Consolidating Statements of Operations and Changes in Net Assets without Donor Restrictions Year Ended June 30, 2022 **Dartmouth-Hitchcock Health and Subsidiaries**

(in thousands of dollars)	Dartmouth- Hitchcock <u>Health</u>	D-H and Subsidiaries	Cheshire and Subsidiaries	NLH	MAHHC and Subsidiaries	APD and Subsidiary	VNH and Subsidiaries	Eliminations	Health System Consolidated
Operating revenue and other support Patient service revenue Contracted revenue Other operating revenue Net assets released from restrictions	\$ 209 38,568 249	\$ 1,751,093 134,388 494,363 13,873	1 \$ 236,645 165 23,794 821	5 \$ 79,754 5 21 7,527 190	\$ 59,041 3,521 4,370 204	\$ 99,403 21 14,587 548	\$ 17,301 - 2,708 9	\$ (60,659) (51,886) -	\$ 2,243,237 77,666 534,031 15,894
Total operating revenue and other support	39,026	2,393,717	261,425	87,492	67,136	114,559	20,018	(112,545)	2,870,828
Operating expenses Salaries		1,091,601	135,116	40,219		47,352	15,534	(44,144)	1,315,407
Employee benefits		266,795				11,169	2,517	(5,579)	322,570
Integrications and medical supplies Purchased services and other	- 25.638	315.589	42,203	9,940 13.067	4,120 18.072	12,237	1,123	(4) (34.670)	049,272 403,862
Medicaid enhancement tax		64,036				3,980			82,725
Depreciation and amortization Interest	- 32,536	64,643 25,365	8,895 914	4,819 1,073	2,483 493	5,595 1,204	523 58	- (29,530)	86,958 32,113
Total operating expenses	58,174	2,406,610	272,305	79,495	65,670	100,512	24,068	(113,927)	2,892,907
Operating (loss) margin	(19,148)	(12,893)	(10,880)	7,997	1,466	14,047	(4,050)	1,382	(22,079)
Non-operating (losses) gains Investment losses, net	(8,026)	(61,039)) (2,163)	(1,114)	(1,663)	(1,373)	(3,155)	(211)	(78,744)
Utter components of net periodic pension and post retirement beneficit income	-	11,902	N				' (L		13,910
Outer (losses) inconte, net Total non-operating losses, net	(3,340) (11,566)	(1,04.1) (50,778)	(24c) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1	(1,113)	(1,484)	- (1,373)		(1,1/1) (1,382)	(71,492)
(Deficiency) excess of revenue over expenses	(30,714)	(63,671)) (11,577)	() 6,884	(18)	12,674	(7,149)		(93,571)
Net assets without donor restrictions Net assets released from restrictions for capital Channe in funded status of pension and other		834	53	460	226			ı	1,573
postretterment benefits postretterment benefits Net assets transferred to (from) affiliates Other changes in net assets	- 7,600 -	(27,860) (19,391) -	(4,496) (4,496) (4,108))	47 795 -	- 2,571 -	- 2,221 -		(32,309) - (23)
(Decrease) increase in net assets without donor restrictions	\$ (23,114)	\$ (110,088)) \$ (11,912)	() \$ 9,417	\$ 1,050	\$ 15,245	\$ (4,928)	ۍ ب	\$ (124,330)

56

Consolidating Statements of Operations and Changes in Net Assets without Donor Restrictions Year Ended June 30, 2021 **Dartmouth-Hitchcock Health and Subsidiaries**

	Dartmouth- Hitchcock	Dartmouth-	Cheshire Medical	Alice Peck Day	New London Hospital	Mt. Ascutney Hospital and	: i	DH Obligated Group	All Other Non- Oblig Group	: !	Health System
(in thousands of dollars)	Health	HITCHCOCK	Center	Memoria	Association	Health Center	Eliminations	Subtotal	Attiliates	Eliminations	Consolidated
Operating revenue and other support Patient service revenue	م	\$ 1,683,612	\$ 230,810	\$ 82,373	\$ 61,814	\$ 59,686	، ب	\$ 2,118,295	\$ 19,992	، ج	\$ 2,138,287
Contracted revenue	7,266	129,880	379	'	162	2,963	(55,753)	84,897	380	(14)	85,263
Other operating revenue Net seeds released from restrictions	29,784 107	404,547	6,775 1 182	1,905 61	4,370	1,175	(37,287)	411,269 14 472	15,490 720	(1,801)	424,958
Total operating revenue and other support	37,247	2,230,670	239,146	84,339	66,546	64,025	(93,040)	2,628,933	36,591	(1,815)	2,663,709
Operating expenses											
Salaries		988,595	118,678	40,567	33,611	29,119	(42,565)	1,168,005	16,800	1,105	1,185,910
Employee benefits		477,1CZ	74 550	1,141	000,0	1,008	(90,109)	806' / 67	3,877	307	302, 142 EAE EDD
iveorcations and medical supplies Purchased services and other	- 19.503	481,863 291.364	41,009 33 737	9,776 12,396	16.591	3,2,2 14,884	(65) (18.065)	370 410 370 410	1,421	- (1.856)	383.949 383.949
Medicaid enhancement tax	-	57,312	8,315	3,075	2,523	1,716	-	72,941		-	72,941
Depreciation and amortization	10	67,666	8,623	3,366	4,364	2,617		86,646	2,275		88,921
Interest	32,324	24,158	936	875	1,077	510	(29,495)	30,385	402	'	30,787
Total operating expenses	51,837	2,162,732	241,942	77,196	72,320	59,789	(95,369)	2,570,447	40,170	(444)	2,610,173
Operating (loss) margin	(14,590)	67,938	(2,796)	7,143	(5,774)	4,236	2,329	58,486	(3,579)	(1,371)	53,536
Non-operating gains (losses) Investment income (losses), net	1,223	172,461	3,546	2,495	4,506	3,875	(137)	187,969	15,807		203,776
Uther components of net periodic pension and post retirement benefit income	,	13.028	547		'	(16)	,	13.559		,	13.559
Other (losses) income, net	(3,540)	(653)	(332)	'	2	194	(2,192)	(6,521)	917	1,371	(4,233)
Total non-operating (losses) gains, net	(2,317)	184,836	3,761	2,495	4,508	4,053	(2,329)	195,007	16,724	1,371	213,102
(Deficiency) excess of revenue over expenses	(16,907)	252,774	965	9,638	(1,266)	8,289	I	253,493	13,145	I	266,638
Net assets without donor restrictions Net assets released from restrictions for capital		1,076	600		108	224	,	2,008	σ	,	2,017
criange in junded status of pension and other postretirement benefits	1	43,047	16,007			78	•	59,132		•	59,132
Net assets transferred to (from) affiliates Other changes in net assets	8,859 -	(13,548) (20)	(42) (35)	- (120)	4,557			(174) (175)	174 (11)		- (186)
(Decrease) increase in net assets without donor restrictions	\$ (8,048)	\$ 283,329	\$ 17,495	\$ 9,518	\$ 3,399	\$ 8,591	۰ ب	\$ 314,284	\$ 13,317	۰ ب	\$ 327,601

Consolidating Statements of Operations and Changes in Net Assets without Donor Restrictions Year Ended June 30, 2021 **Dartmouth-Hitchcock Health and Subsidiaries**

(in thousands of dollars)	D-HH and Other Subsidiaries	S	D-H and ubsidiaries	Che Sub	Cheshire and Subsidiaries	NLH and Subsidiaries	nd aries	MAHHC and Subsidiaries	APD and Subsidiary	VNH and Subsidiaries	nd Irries	Eliminations	He Sy: Conse	Health System Consolidated
Operating revenue and other support Patient service revenue Contracted revenue Other operating revenue Net assets released from restrictions	\$ 7,266 29,784 197	ن ې	1,683,612 130,261 406,911 13,290	¢	230,810 379 6,862 1,196	9 9	61,814 161 4,370 199	\$ 59,672 2,963 2,839 201	\$ 82,373 - 11,997 118	ъ	20,006 { - 1,283 -	\$ (55,767) (39,088) -	÷	2,138,287 85,263 424,958 15,201
Total operating revenue and other support	37,247		2,234,074		239,247	9	66,544	65,675	94,488		21,289	(94,855)		2,663,709
Operating expenses Salaries	,		988,595		118,711	e	33,611	29,986	44,240		12,227	(41,460)		1,185,910
Employee benefits	'		251,774		29,994		6,550	7,820	7,884		2,972	(4,852)		302,142
Medications and medical supplies Durchased services and other	- 10 החה		481,863 294 228		41,669 33 912	÷	7,604 16 589	3,270 15 395	9,784 15,455		1,418 8 786	(85)		545,523 383 949
Medicaid enhancement tax			57,312		8,315	-	2,523	1,716	3,075			-		72,941
Depreciation and amortization	10		67,666		8,752		4,364	2,741	5,003		385	'		88,921
Interest	32,324		24,158		936		1,077	510	1,217		09	(29,495)		30,787
Total operating expenses	51,839		2,165,596		242,289	7	72,318	61,438	86,658		25,848	(95,813)		2,610,173
Operating (loss) margin	(14,592)		68,478		(3,042))	(5,774)	4,237	7,830		(4,559)	958		53,536
Non-operating gains (losses) Investment income (losses), net Other commonents of net periodic pension and post	1,223		179,357		6,317		4,506	4,066	2,472		5,972	(137)		203,776
retirement benefit income			13,028		547			(16)				,		13,559
Other (losses) income, net	(3,540)		(653)		(346)		2	207			918	(821)		(4,233)
Total non-operating (losses) gains, net	(2,317)	(191,732		6,518		4,508	4,257	2,472		6,890	(958)		213,102
(Deficiency) excess of revenue over expenses	(16,909)	-	260,210		3,476	0	(1,266)	8,494	10,302		2,331	'		266,638
Net assets without donor restrictions Net assets released from restrictions for capital Channe in funded status of nemsion and other			1,085		600		108	224	·					2,017
postretirementado docto portado a postretiremento Not accorde transformed to <i>(fram</i>) offiliated	- 0 050		43,047 /12 548/		16,007		- 1 667	78	·		- 120			59,132
Net assets transferred to (notif) anniates Other changes in net assets	-		(13, 340)		- (46)				- (120)	((186)
(Decrease) increase in net assets without donor restrictions	\$ (8,050)	\$	290,774	÷	20,037	÷	3,399	\$ 8,796	\$ 10,182	÷	2,463	' ج	÷	327,601

1. Basis of Presentation

The accompanying supplemental consolidating information includes the consolidating balance sheet and the consolidating statement of operations and changes in net assets without donor restrictions of D-HH and its subsidiaries. All significant intercompany accounts and transactions between D-HH and its subsidiaries have been eliminated. The consolidating information presented is prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America consistent with the consolidated financial statements. The consolidating information is presented for purposes of additional analysis of the consolidated financial statements and is not required as part of the basic financial statements.